{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:34:32Z","timestamp":1786696472587,"version":"build-2736575974"},"reference-count":668,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["899163"],"award-info":[{"award-number":["899163"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Talanta"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.talanta.2026.130079","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:08:39Z","timestamp":1780474119000},"page":"130079","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Advances in analytical methods for regulatory complement proteins in research and clinical applications"],"prefix":"10.1016","volume":"310","author":[{"given":"Ferdinand","family":"Waescher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Spitzenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Pauly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje J.","family":"Baeumner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.talanta.2026.130079_bib1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3389\/fimmu.2015.00257","article-title":"Complement System Part II: Role in Immunity","volume":"6","author":"Merle","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement System Part I - Molecular Mechanisms of Activation and Regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib3","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.4049\/jimmunol.0903678","article-title":"Molecular intercommunication between the complement and coagulation systems","volume":"185","author":"Amara","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"Dunkelberger","year":"2010","journal-title":"Cell Res."},{"key":"10.1016\/j.talanta.2026.130079_bib5","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib6","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1096\/fj.11-186460","article-title":"Monomeric C-reactive protein modulates classic complement activation on necrotic cells","volume":"25","author":"Mihlan","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.talanta.2026.130079_bib7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00281-017-0642-0","article-title":"Structural and functional diversity of collectins and ficolins and their relationship to disease","volume":"40","author":"Howard","year":"2018","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.talanta.2026.130079_bib8","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1016\/j.molimm.2007.11.003","article-title":"The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb)","volume":"45","author":"Bexborn","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib9","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3389\/fimmu.2020.00530","article-title":"Assessment of the Role of C3(H2O) in the Alternative Pathway","volume":"11","author":"Fromell","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.molimm.2019.07.032","article-title":"Is generation of C3(H2O) necessary for activation of the alternative pathway in real life?","volume":"114","author":"Ekdahl","year":"2019","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10587","article-title":"Structural basis of complement membrane attack complex formation","volume":"7","author":"Serna","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.talanta.2026.130079_bib12","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev.iy.04.040186.002443","article-title":"The membrane attack complex of complement","volume":"4","author":"M\u00fcller-Eberhard","year":"1986","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/pro.5560060201","article-title":"The internal thioester and the covalent binding properties of the complement proteins C3 and C4","volume":"6","author":"Law","year":"1997","journal-title":"Protein Sci."},{"key":"10.1016\/j.talanta.2026.130079_bib14","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1182\/blood.V89.8.2863","article-title":"C3a and C5a Stimulate Chemotaxis of Human Mast Cells","volume":"89","author":"Hartmann","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.talanta.2026.130079_bib15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12967-024-05909-x","article-title":"Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study","volume":"23","author":"Schikora","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib16","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1177\/1352458519887905","article-title":"Cerebrospinal fluid complement system biomarkers in demyelinating disease","volume":"26","author":"Zelek","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.talanta.2026.130079_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12879-016-2107-9","article-title":"Increased activity of the complement system in cerebrospinal fluid of the patients with Non-HIV Cryptococcal meningitis","volume":"17","author":"Shen","year":"2017","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.talanta.2026.130079_bib18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s13075-016-1123-x","article-title":"The complement system is activated in synovial fluid from subjects with knee injury and from patients with osteoarthritis","volume":"18","author":"Struglics","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.talanta.2026.130079_bib19","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nri2620","article-title":"Complement regulators and inhibitory proteins","volume":"9","author":"Zipfel","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib20","first-page":"4195","article-title":"Complement Regulatory Activity of Normal Human Intraocular Fluid Is Mediated by MCP, DAF, and CD59","volume":"41","author":"Sohn","year":"2000","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.talanta.2026.130079_bib21","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1016\/j.molimm.2008.06.028","article-title":"Biological activities of C1 inhibitor","volume":"45","author":"Davis","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib22","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.4049\/jimmunol.2300333","article-title":"Diverse Functions of C4b-Binding Protein in Health and Disease","volume":"211","author":"Werner","year":"2023","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib23","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.molimm.2004.02.005","article-title":"The human complement factor H: functional roles, genetic variations and disease associations","volume":"41","author":"Rodr\u00edguez de C\u00f3rdoba","year":"2004","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib24","doi-asserted-by":"crossref","first-page":"28540","DOI":"10.1074\/jbc.M704354200","article-title":"C4b-binding protein and factor H compensate for the loss of membrane-bound complement inhibitors to protect apoptotic cells against excessive complement attack","volume":"282","author":"Trouw","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.talanta.2026.130079_bib25","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.4049\/jimmunol.1801545","article-title":"Self versus Nonself Discrimination by the Soluble Complement Regulators Factor H and FHL-1","volume":"202","author":"Dopler","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib26","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.4049\/jimmunol.1401613","article-title":"Identification of factor H-like protein 1 as the predominant complement regulator in Bruch's membrane: implications for age-related macular degeneration","volume":"193","author":"Clark","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib27","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.it.2015.04.008","article-title":"Factor H-related proteins determine complement-activating surfaces","volume":"36","author":"J\u00f3zsi","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1135490","article-title":"The human factor H protein family - an update","volume":"15","author":"S\u00e1ndor","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib29","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.semcdb.2017.12.018","article-title":"Complement factor H family proteins in their non-canonical role as modulators of cellular functions","volume":"85","author":"J\u00f3zsi","year":"2019","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.talanta.2026.130079_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/imr.13166","article-title":"The Factor H protein family: The switchers of the complement alternative pathway","volume":"313","author":"Lucientes-Continente","year":"2023","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.talanta.2026.130079_bib31","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0161-5890(94)00157-V","article-title":"Human factor H and C4b-binding protein serve as factor I-cofactors both encompassing inactivation of C3b and C4b","volume":"32","author":"Seya","year":"1995","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib32","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/oxfordjournals.jbchem.a123799","article-title":"Factor I-dependent inactivation of human complement C4b of the classical pathway by C3b\/C4b receptor (CR1, CD35) and membrane cofactor protein (MCP, CD46)","volume":"111","author":"Masaki","year":"1992","journal-title":"J. Biochem."},{"key":"10.1016\/j.talanta.2026.130079_bib33","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.4049\/jimmunol.179.4.2600","article-title":"Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly","volume":"179","author":"Spitzer","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib34","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1172\/JCI106462","article-title":"Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase","volume":"49","author":"Bokisch","year":"1970","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.talanta.2026.130079_bib35","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.intimp.2007.07.014","article-title":"Structure and function of human plasma carboxypeptidase N, the anaphylatoxin inactivator","volume":"7","author":"Skidgel","year":"2007","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.talanta.2026.130079_bib36","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1007\/s00018-011-0684-8","article-title":"Clusterin facilitates in vivo clearance of extracellular misfolded proteins","volume":"68","author":"Wyatt","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.talanta.2026.130079_bib37","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.4049\/jimmunol.151.4.2159","article-title":"Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9","volume":"151","author":"Tschopp","year":"1993","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib38","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1365-2249.1993.tb05956.x","article-title":"Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9","volume":"92","author":"Milis","year":"1993","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib39","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev.cb.07.110191.001423","article-title":"Structure and biological role of vitronectin","volume":"7","author":"Preissner","year":"1991","journal-title":"Annu. Rev. Cell Biol."},{"key":"10.1016\/j.talanta.2026.130079_bib40","doi-asserted-by":"crossref","first-page":"11030","DOI":"10.1016\/S0021-9258(18)99123-4","article-title":"Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma","volume":"266","author":"Jenne","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.talanta.2026.130079_bib41","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.celrep.2012.02.003","article-title":"Assembly and regulation of the membrane attack complex based on structures of C5b6 and sC5b9","volume":"1","author":"Hadders","year":"2012","journal-title":"Cell Rep."},{"key":"10.1016\/j.talanta.2026.130079_bib42","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/glia.24355","article-title":"Complement receptor 1 is expressed on brain cells and in the human brain","volume":"71","author":"Daskoulidou","year":"2023","journal-title":"Glia"},{"key":"10.1016\/j.talanta.2026.130079_bib43","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.molimm.2008.09.026","article-title":"Complement Receptor 1: disease associations and therapeutic implications","volume":"46","author":"Khera","year":"2009","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib44","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.4049\/jimmunol.168.6.2782","article-title":"Complement receptor type 1 (CD35) mediates inhibitory signals in human B lymphocytes","volume":"168","author":"J\u00f3zsi","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib45","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.imbio.2011.06.003","article-title":"CD46 processing: a means of expression","volume":"217","author":"Ni Choileain","year":"2012","journal-title":"Immunobiology"},{"key":"10.1016\/j.talanta.2026.130079_bib46","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.coi.2021.04.005","article-title":"Membrane cofactor protein (MCP; CD46): deficiency states and pathogen connections","volume":"72","author":"Liszewski","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib47","first-page":"532","article-title":"Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues","volume":"65","author":"Meri","year":"1991","journal-title":"Lab. Invest."},{"key":"10.1016\/j.talanta.2026.130079_bib48","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1084\/jem.163.1.221","article-title":"Decay-accelerating factor is present on cultured human umbilical vein endothelial cells","volume":"163","author":"Asch","year":"1986","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib49","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1084\/jem.162.1.75","article-title":"Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria","volume":"162","author":"Kinoshita","year":"1985","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib50","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1046\/j.1365-2567.2000.00086.x","article-title":"Structure\/function studies of human decay-accelerating factor","volume":"101","author":"Brodbeck","year":"2000","journal-title":"Immunology"},{"key":"10.1016\/j.talanta.2026.130079_bib51","doi-asserted-by":"crossref","first-page":"27398","DOI":"10.1074\/jbc.M603690200","article-title":"Defining the CD59-C9 binding interaction","volume":"281","author":"Huang","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.talanta.2026.130079_bib52","doi-asserted-by":"crossref","first-page":"13675","DOI":"10.1016\/S0021-9258(18)42266-1","article-title":"The human complement regulatory protein CD59 binds to the alpha-chain of C8 and to the \u201cb\u201ddomain of C9","volume":"267","author":"Ninomiya","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.talanta.2026.130079_bib53","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.3389\/fimmu.2019.02892","article-title":"Human Dendritic Cells Express the Complement Receptor Immunoglobulin Which Regulates T Cell Responses","volume":"10","author":"Munawara","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib54","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1016\/j.molimm.2008.07.011","article-title":"A role of macrophage complement receptor CRIg in immune clearance and inflammation","volume":"45","author":"He","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib55","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature05263","article-title":"Structure of C3b in complex with CRIg gives insights into regulation of complement activation","volume":"444","author":"Wiesmann","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.talanta.2026.130079_bib56","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1124\/pharmrev.120.000072","article-title":"Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics","volume":"73","author":"Garred","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.talanta.2026.130079_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.578069","article-title":"Therapeutic Lessons to be Learned From the Role of Complement Regulators as Double-Edged Sword in Health and Disease","volume":"11","author":"de Boer","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib58","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.molimm.2011.05.001","article-title":"Complement deficiency states and associated infections","volume":"48","author":"Skattum","year":"2011","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib59","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1016\/j.molimm.2009.04.029","article-title":"Complement in human diseases: Lessons from complement deficiencies","volume":"46","author":"Botto","year":"2009","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib60","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1007\/s12325-022-02401-0","article-title":"Hereditary Angioedema: Diagnosis, Clinical Implications, and Pathophysiology","volume":"40","author":"Sinnathamby","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.talanta.2026.130079_bib61","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.molimm.2017.05.020","article-title":"The role of the complement system in hereditary angioedema","volume":"89","author":"Csuka","year":"2017","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib62","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1007\/s00018-021-03796-9","article-title":"The complement system in age-related macular degeneration","volume":"78","author":"Armento","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.talanta.2026.130079_bib63","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41467-020-14499-3","article-title":"Increased circulating levels of Factor H-Related Protein 4 are strongly associated with age-related macular degeneration","volume":"11","author":"Cipriani","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.talanta.2026.130079_bib64","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/eye.2017.245","article-title":"Genetics and genetic testing for age-related macular degeneration","volume":"32","author":"Warwick","year":"2018","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.talanta.2026.130079_bib65","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.molimm.2016.11.016","article-title":"The complement system in age-related macular degeneration: A review of rare genetic variants and implications for personalized treatment","volume":"84","author":"Geerlings","year":"2017","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib66","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ng.3448","article-title":"A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants","volume":"48","author":"Fritsche","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.talanta.2026.130079_bib67","doi-asserted-by":"crossref","first-page":"8828","DOI":"10.1167\/iovs.11-7933","article-title":"Complement factor D in age-related macular degeneration","volume":"52","author":"Stanton","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.talanta.2026.130079_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000836","article-title":"Genetic and functional dissection of HTRA1 and LOC387715 in age-related macular degeneration","volume":"6","author":"Yang","year":"2010","journal-title":"PLoS Genet."},{"key":"10.1016\/j.talanta.2026.130079_bib69","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1167\/iovs.09-3850","article-title":"ARMS2 is a constituent of the extracellular matrix providing a link between familial and sporadic age-related macular degenerations","volume":"51","author":"Kortvely","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.talanta.2026.130079_bib70","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/ejhg.2008.140","article-title":"Variation near complement factor I is associated with risk of advanced AMD","volume":"17","author":"Fagerness","year":"2009","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.talanta.2026.130079_bib71","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1056\/NEJMoa072618","article-title":"Complement C3 variant and the risk of age-related macular degeneration","volume":"357","author":"Yates","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib72","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1126\/science.1133807","article-title":"HTRA1 promoter polymorphism in wet age-related macular degeneration","volume":"314","author":"Dewan","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.talanta.2026.130079_bib73","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1080\/07853890601097030","article-title":"Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: Characterization, ethnic distribution and evolutionary implications","volume":"38","author":"Hageman","year":"2006","journal-title":"Ann. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib74","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/ng1890","article-title":"A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration","volume":"38","author":"Hughes","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.talanta.2026.130079_bib75","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/ng1750","article-title":"Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration","volume":"38","author":"Gold","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.talanta.2026.130079_bib76","first-page":"S2","article-title":"Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system","volume":"29","author":"Bakri","year":"2023","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.talanta.2026.130079_bib77","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.exer.2011.06.002","article-title":"Retinal pigment epithelial expression of complement regulator CD46 is altered early in the course of geographic atrophy","volume":"93","author":"Vogt","year":"2011","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.talanta.2026.130079_bib78","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41581-021-00424-4","article-title":"Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics","volume":"17","author":"Fakhouri","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.talanta.2026.130079_bib79","first-page":"400","article-title":"The genetics of atypical hemolytic uremic syndrome","volume":"30","author":"Feitz","year":"2018","journal-title":"Med. Genet."},{"key":"10.1016\/j.talanta.2026.130079_bib80","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/1744-9987.12763","article-title":"Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment","volume":"23","author":"Raina","year":"2019","journal-title":"Ther. Apher. Dial."},{"key":"10.1016\/j.talanta.2026.130079_bib81","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","article-title":"Atypical hemolytic uremic syndrome","volume":"33","author":"Kavanagh","year":"2013","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.talanta.2026.130079_bib82","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1371\/journal.pgen.0030041","article-title":"Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome","volume":"3","author":"Zipfel","year":"2007","journal-title":"PLoS Genet."},{"key":"10.1016\/j.talanta.2026.130079_bib83","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int."},{"key":"10.1016\/j.talanta.2026.130079_bib84","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.molimm.2011.04.005","article-title":"Dense deposit disease","volume":"48","author":"Smith","year":"2011","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib85","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1172\/JCI43343","article-title":"Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation","volume":"120","author":"Mart\u00ednez-Barricarte","year":"2010","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.talanta.2026.130079_bib86","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/jmg.2005.038315","article-title":"Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease)","volume":"43","author":"Abrera-Abeleda","year":"2006","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.talanta.2026.130079_bib87","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/ndt\/gfy064","article-title":"Defective gene expression of the membrane complement inhibitor CD46 in patients with progressive immunoglobulin A nephropathy","volume":"34","author":"Coppo","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.talanta.2026.130079_bib88","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.kint.2017.03.043","article-title":"Circulating complement factor H-related proteins 1 and 5 correlate with disease activity in IgA nephropathy","volume":"92","author":"Medjeral-Thomas","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.talanta.2026.130079_bib89","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2215\/CJN.07420716","volume":"12","author":"Rodrigues","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.talanta.2026.130079_bib90","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1681\/ASN.2015010012","article-title":"Rare Variants in the Complement Factor H-Related Protein 5 Gene Contribute to Genetic Susceptibility to IgA Nephropathy","volume":"27","author":"Zhai","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.talanta.2026.130079_bib91","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1681\/ASN.2014010096","article-title":"Variants in Complement Factor H and Complement Factor H-Related Protein Genes, CFHR3 and CFHR1, Affect Complement Activation in IgA Nephropathy","volume":"26","author":"Zhu","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.talanta.2026.130079_bib92","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1681\/ASN.2014101000","article-title":"Current Understanding of the Role of Complement in IgA Nephropathy","volume":"26","author":"Maillard","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.talanta.2026.130079_bib93","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ng.787","article-title":"Genome-wide association study identifies susceptibility loci for IgA nephropathy","volume":"43","author":"Gharavi","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.talanta.2026.130079_bib94","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.talanta.2026.130079_bib95","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/ejh.12543","article-title":"Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review","volume":"95","author":"Devalet","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.talanta.2026.130079_bib96","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","article-title":"Paroxysmal nocturnal hemoglobinuria","volume":"124","author":"Brodsky","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.talanta.2026.130079_bib97","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.exphem.2007.01.046","article-title":"The pathophysiology of paroxysmal nocturnal hemoglobinuria","volume":"35","author":"Parker","year":"2007","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.talanta.2026.130079_bib98","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood-2005-04-1717","article-title":"Diagnosis and management of paroxysmal nocturnal hemoglobinuria","volume":"106","author":"Parker","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.talanta.2026.130079_bib99","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/imr.12715","article-title":"CHAPLE syndrome uncovers the primary role of complement in a familial form of Waldmann's disease","volume":"287","author":"Ozen","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.talanta.2026.130079_bib100","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer Disease: An Update on Pathobiology and Treatment Strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.talanta.2026.130079_bib101","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00281-017-0662-9","article-title":"Complement in the pathogenesis of Alzheimer's disease","volume":"40","author":"Morgan","year":"2018","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.talanta.2026.130079_bib102","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s12031-018-1045-y","article-title":"Updated Meta-Analysis of BIN1, CR1, MS4A6A, CLU, and ABCA7 Variants in Alzheimer's Disease","volume":"64","author":"Almeida","year":"2018","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.talanta.2026.130079_bib103","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.disamonth.2010.06.001","article-title":"Alzheimer disease","volume":"56","author":"Castellani","year":"2010","journal-title":"Dis. Mon."},{"key":"10.1016\/j.talanta.2026.130079_bib104","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/ng.440","article-title":"Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease","volume":"41","author":"Harold","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.talanta.2026.130079_bib105","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/ng.439","article-title":"Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease","volume":"41","author":"Lambert","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.talanta.2026.130079_bib106","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41568-019-0210-0","article-title":"Context-dependent roles of complement in cancer","volume":"19","author":"Roumenina","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.talanta.2026.130079_bib107","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nri.2017.97","article-title":"Complement in cancer: untangling an intricate relationship","volume":"18","author":"Reis","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib108","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1146\/annurev.iy.10.040192.004113","article-title":"Complement deficiencies","volume":"10","author":"Colten","year":"1992","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib109","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1128\/CMR.4.3.359","article-title":"Infectious diseases associated with complement deficiencies","volume":"4","author":"Figueroa","year":"1991","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.talanta.2026.130079_bib110","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.jaci.2018.01.015","article-title":"Hereditary angioedema with normal C1 inhibitor: Four types and counting","volume":"141","author":"Zuraw","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib111","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1710-1492-6-14","article-title":"Acquired angioedema","volume":"6","author":"Cicardi","year":"2010","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib112","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration","volume":"392","author":"Mitchell","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.talanta.2026.130079_bib113","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.molimm.2015.02.032","article-title":"Age-related macular degeneration and the role of the complement system","volume":"67","author":"McHarg","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib114","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/eye.2011.37","article-title":"Complement in age-related macular degeneration: a focus on function","volume":"25","author":"Bradley","year":"2011","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.talanta.2026.130079_bib115","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.ophtha.2015.07.029","article-title":"Joint Associations of Diet, Lifestyle, and Genes with Age-Related Macular Degeneration","volume":"122","author":"Meyers","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.talanta.2026.130079_bib116","doi-asserted-by":"crossref","first-page":"ORSF28","DOI":"10.1167\/iovs.13-13234","article-title":"Genetic and environmental underpinnings to age-related ocular diseases","volume":"54","author":"Seddon","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.talanta.2026.130079_bib117","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2415-10-31","article-title":"Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis","volume":"10","author":"Chakravarthy","year":"2010","journal-title":"BMC Ophthalmol."},{"key":"10.1016\/j.talanta.2026.130079_bib118","doi-asserted-by":"crossref","first-page":"30192","DOI":"10.1074\/jbc.M110.103986","article-title":"Impaired binding of the age-related macular degeneration-associated complement factor H 402H allotype to Bruch's membrane in human retina","volume":"285","author":"Clark","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.talanta.2026.130079_bib119","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.4049\/jimmunol.178.6.3831","article-title":"Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein","volume":"178","author":"Laine","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib120","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.ajhg.2021.05.015","article-title":"Beyond factor H: The impact of genetic-risk variants for age-related macular degeneration on circulating factor-H-like 1 and factor-H-related protein concentrations","volume":"108","author":"Cipriani","year":"2021","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.talanta.2026.130079_bib121","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.neuron.2012.06.018","article-title":"Mechanisms of age-related macular degeneration","volume":"75","author":"Ambati","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.talanta.2026.130079_bib122","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.kint.2018.02.029","article-title":"Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome","volume":"94","author":"Schaefer","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.talanta.2026.130079_bib123","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fped.2018.00220","article-title":"Short- and Long-Term Renal Outcome of Hemolytic-Uremic Syndrome in Childhood","volume":"6","author":"Vaterodt","year":"2018","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.talanta.2026.130079_bib124","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.2147\/JMDH.S245620","article-title":"Atypical Hemolytic-Uremic Syndrome: Genetic Basis, Clinical Manifestations, and a Multidisciplinary Approach to Management","volume":"16","author":"Yerigeri","year":"2023","journal-title":"J. Multidiscip. Healthc."},{"key":"10.1016\/j.talanta.2026.130079_bib125","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2010030315","article-title":"Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome","volume":"21","author":"Dragon-Durey","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.talanta.2026.130079_bib126","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00467-010-1446-9","article-title":"DEAP-HUS: deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome","volume":"25","author":"Zipfel","year":"2010","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.talanta.2026.130079_bib127","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00467-011-2059-7","article-title":"Clinical features and outcomes of 98 children and adults with dense deposit disease","volume":"27","author":"Lu","year":"2012","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.talanta.2026.130079_bib128","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1681\/ASN.2010040355","article-title":"Predicting the risk for dialysis or death in IgA nephropathy","volume":"22","author":"Berthoux","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.talanta.2026.130079_bib129","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1093\/ndt\/gfq812","article-title":"Immunostaining findings in IgA nephropathy: correlation with histology and clinical outcome in the Oxford classification patient cohort","volume":"26","author":"Bellur","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.talanta.2026.130079_bib130","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/modpathol.3800773","article-title":"Dense deposit disease is not a membranoproliferative glomerulonephritis","volume":"20","author":"Walker","year":"2007","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.talanta.2026.130079_bib131","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1056\/NEJMc1107484","article-title":"Combined C3b and factor B autoantibodies and MPGN type II","volume":"365","author":"Chen","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib132","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.molimm.2010.02.002","article-title":"Anti-factor B autoantibody in dense deposit disease","volume":"47","author":"Strobel","year":"2010","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib133","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000382134","article-title":"New Insights into the Pathogenesis of IgA Nephropathy","volume":"1","author":"Novak","year":"2015","journal-title":"Kidney Dis."},{"key":"10.1016\/j.talanta.2026.130079_bib134","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1681\/ASN.2005090923","article-title":"Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease","volume":"17","author":"Roos","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.talanta.2026.130079_bib135","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1182\/blood-2012-09-311381","article-title":"Thrombosis in paroxysmal nocturnal hemoglobinuria","volume":"121","author":"Hill","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.talanta.2026.130079_bib136","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1056\/NEJMc1707173","article-title":"Loss of CD55 in Eculizumab-Responsive Protein-Losing Enteropathy","volume":"377","author":"Kurolap","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib137","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1056\/NEJMoa1615887","article-title":"CD55 Deficiency, Early-Onset Protein-Losing Enteropathy, and Thrombosis","volume":"377","author":"Ozen","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib138","article-title":"Microglia in Alzheimer's disease","volume":"2014","author":"Li","year":"2014","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.talanta.2026.130079_bib139","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.bcp.2014.01.008","article-title":"Microglial dysfunction in brain aging and Alzheimer's disease","volume":"88","author":"Mosher","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.talanta.2026.130079_bib140","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF02890024","article-title":"Complement activation in amyloid plaques in Alzheimer's dementia","volume":"56","author":"Eikelenboom","year":"1989","journal-title":"Virchows Arch. B Cell Pathol. Incl. Mol. Pathol."},{"key":"10.1016\/j.talanta.2026.130079_bib141","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/BF00687336","article-title":"Immuno-electron-microscopic localization of complements in amyloid fibrils of senile plaques","volume":"63","author":"Ishii","year":"1984","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.talanta.2026.130079_bib142","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00685397","article-title":"Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study","volume":"57","author":"Eikelenboom","year":"1982","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.talanta.2026.130079_bib143","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0002-9440(10)64604-4","article-title":"Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis","volume":"157","author":"Singhrao","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.talanta.2026.130079_bib144","first-page":"1247","article-title":"Differential expression of individual complement regulators in the brain and choroid plexus","volume":"79","author":"Singhrao","year":"1999","journal-title":"Lab. Invest."},{"key":"10.1016\/j.talanta.2026.130079_bib145","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13195-017-0319-x","article-title":"The clinical significance of plasma clusterin and A\u03b2 in the longitudinal follow-up of patients with Alzheimer's disease","volume":"9","author":"Hsu","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.talanta.2026.130079_bib146","doi-asserted-by":"crossref","first-page":"208.e1","DOI":"10.1016\/j.neurobiolaging.2015.09.009","article-title":"A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin","volume":"37","author":"Deming","year":"2016","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.talanta.2026.130079_bib147","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3233\/JAD-150036","article-title":"Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease","volume":"46","author":"Jongbloed","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.talanta.2026.130079_bib148","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028527","article-title":"Plasma biomarkers of brain atrophy in Alzheimer's disease","volume":"6","author":"Thambisetty","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.talanta.2026.130079_bib149","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3389\/fnins.2019.00164","article-title":"Clusterin in Alzheimer's Disease: Mechanisms, Genetics, and Lessons From Other Pathologies","volume":"13","author":"Foster","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.talanta.2026.130079_bib150","article-title":"Intracellular clusterin interacts with brain isoforms of the bridging integrator 1 and with the microtubule-associated protein Tau in Alzheimer's disease","volume":"9","author":"Zhou","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.talanta.2026.130079_bib151","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s40478-020-01079-1","article-title":"Clusterin ameliorates tau pathology in vivo by inhibiting fibril formation","volume":"8","author":"Wojtas","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.talanta.2026.130079_bib152","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70458","article-title":"The Alzheimer's disease-associated complement receptor 1 variant confers risk by impacting glial phagocytosis","volume":"21","author":"Daskoulidou","year":"2025","journal-title":"Alzheimer's Dement."},{"key":"10.1016\/j.talanta.2026.130079_bib153","doi-asserted-by":"crossref","first-page":"910","DOI":"10.5858\/arpa.2013-0064-OA","article-title":"Systematic immunohistochemical analysis of the expression of CD46, CD55, and CD59 in colon cancer","volume":"138","author":"Shang","year":"2014","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.talanta.2026.130079_bib154","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00262-005-0055-0","article-title":"Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients","volume":"55","author":"Watson","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.talanta.2026.130079_bib155","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s00262-003-0402-y","article-title":"Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients","volume":"52","author":"Durrant","year":"2003","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.talanta.2026.130079_bib156","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1046\/j.1440-1746.2001.02418.x","article-title":"Polymorphic expression of decay-accelerating factor in human colorectal cancer","volume":"16","author":"Nakagawa","year":"2001","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.talanta.2026.130079_bib157","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0959-8049(98)00290-1","article-title":"Expression and regulation by interferon-gamma of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours","volume":"35","author":"Schmitt","year":"1999","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.talanta.2026.130079_bib158","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1699-0463.1998.tb00233.x","article-title":"The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues","volume":"106","author":"Thorsteinsson","year":"1998","journal-title":"APMIS"},{"key":"10.1016\/j.talanta.2026.130079_bib159","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/(SICI)1096-9098(199703)64:3<222::AID-JSO9>3.0.CO;2-C","article-title":"Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A","volume":"64","author":"Juhl","year":"1997","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.talanta.2026.130079_bib160","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.1365-2249.1998.00581.x","article-title":"Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance","volume":"113","author":"Varsano","year":"1998","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib161","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1038\/sj.bjc.6690604","article-title":"Expression of membrane cofactor protein (MCP, CD46) in human liver diseases","volume":"80","author":"Kinugasa","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.talanta.2026.130079_bib162","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.febslet.2012.01.039","article-title":"HBXIP upregulates CD46, CD55 and CD59 through ERK1\/2\/NF-\u03baB signaling to protect breast cancer cells from complement attack","volume":"586","author":"Cui","year":"2012","journal-title":"FEBS Lett."},{"key":"10.1016\/j.talanta.2026.130079_bib163","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/(SICI)1097-0215(19970106)70:1<14::AID-IJC3>3.0.CO;2-9","article-title":"Complement-regulatory proteins in ovarian malignancies","volume":"70","author":"Bj\u00f8rge","year":"1997","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.talanta.2026.130079_bib164","first-page":"1455","article-title":"Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease","volume":"151","author":"Simpson","year":"1997","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.talanta.2026.130079_bib165","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/ijc.23676","article-title":"Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection","volume":"123","author":"Varela","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.talanta.2026.130079_bib166","first-page":"1884","article-title":"Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas","volume":"37","author":"Goslings","year":"1996","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.talanta.2026.130079_bib167","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1002\/1097-0142(19940601)73:11<2808::AID-CNCR2820731125>3.0.CO;2-P","article-title":"Protection of thyroid cancer cells by complement-regulatory factors","volume":"73","author":"Yamakawa","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.talanta.2026.130079_bib168","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1034\/j.1600-0609.2000.80097.x","article-title":"Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies","volume":"64","author":"Guc","year":"2000","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.talanta.2026.130079_bib169","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1365-2141.1992.tb06431.x","article-title":"Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies","volume":"82","author":"Hara","year":"1992","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.talanta.2026.130079_bib170","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.ejca.2014.05.005","article-title":"The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack","volume":"50","author":"Kesselring","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.talanta.2026.130079_bib171","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1600-0714.2006.00466.x","article-title":"Expression of complement restriction factors (CD46, CD55 & CD59) in head and neck squamous cell carcinomas","volume":"35","author":"Ravindranath","year":"2006","journal-title":"J. Oral Pathol. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib172","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12935-019-1027-3","article-title":"Role of the complement system in the tumor microenvironment","volume":"19","author":"Zhang","year":"2019","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.talanta.2026.130079_bib173","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/ni.1917","article-title":"Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells","volume":"11","author":"Cardone","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib174","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/sj.bjc.6600614","article-title":"Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells","volume":"87","author":"Junnikkala","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.talanta.2026.130079_bib175","doi-asserted-by":"crossref","first-page":"935","DOI":"10.4049\/jimmunol.167.2.935","article-title":"Regulation of complement classical pathway by association of C4b-binding protein to the surfaces of SK-OV-3 and Caov-3 ovarian adenocarcinoma cells","volume":"167","author":"Holmberg","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib176","doi-asserted-by":"crossref","first-page":"6310","DOI":"10.1158\/0008-5472.CAN-03-2328","article-title":"Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement","volume":"64","author":"Ajona","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.talanta.2026.130079_bib177","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1046\/j.1365-2249.2003.02066.x","article-title":"Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid","volume":"131","author":"Donin","year":"2003","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib178","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13223-019-0362-1","article-title":"Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study","volume":"15","author":"Li","year":"2019","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib179","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1186\/1939-4551-3-S3-S29","article-title":"Recombinant and plasma-purified human c1 inhibitor for the treatment of hereditary angioedema","volume":"3","author":"Frank","year":"2010","journal-title":"World Allergy Organ. J."},{"key":"10.1016\/j.talanta.2026.130079_bib180","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202350816","article-title":"Complement-targeted therapeutics: Are we there yet, or just getting started?","volume":"54","author":"Ricklin","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib187","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2147\/JBM.S9576","article-title":"Cinryze as the first approved C1 inhibitor in the USA for the treatment of hereditary angioedema: approval, efficacy and safety","volume":"1","author":"Lunn","year":"2010","journal-title":"J. Blood Med"},{"key":"10.1016\/j.talanta.2026.130079_bib188","first-page":"293","article-title":"Cinryze, a human plasma-derived c1 esterase inhibitor for prophylaxis of hereditary angioedema","volume":"34","author":"Cocchio","year":"2009","journal-title":"P T"},{"key":"10.1016\/j.talanta.2026.130079_bib189","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.jaip.2019.01.054","article-title":"Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks","volume":"7","author":"Craig","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.talanta.2026.130079_bib190","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1613627","article-title":"Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor","volume":"376","author":"Longhurst","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib191","first-page":"562","article-title":"Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children, Pediatr","volume":"30","author":"Reshef","year":"2019","journal-title":"Allerg. Immunol. (Paris)"},{"key":"10.1016\/j.talanta.2026.130079_bib192","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1111\/trf.12678","article-title":"Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema","volume":"54","author":"Feussner","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.talanta.2026.130079_bib193","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/NAN.0000000000000365","article-title":"Advances in Hereditary Angioedema: The Prevention of Angioedema Attacks With Subcutaneous C1-Inhibitor Replacement Therapy","volume":"43","author":"Lumry","year":"2020","journal-title":"J. Infusion Nurs."},{"key":"10.1016\/j.talanta.2026.130079_bib194","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.883743","article-title":"The Hidden Side of Complement Regulator C4BP: Dissection and Evaluation of Its Immunomodulatory Activity","volume":"13","author":"Serrano","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib195","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3389\/fimmu.2018.01945","article-title":"Chimeric Proteins Containing MAP-1 and Functional Domains of C4b-Binding Protein Reveal Strong Complement Inhibitory Capacities","volume":"9","author":"Hertz","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib196","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.726801","article-title":"Serum Complement Activation by C4BP-IgM Fusion Protein Can Restore Susceptibility to Antibiotics in Neisseria gonorrhoeae","volume":"12","author":"Bettoni","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib197","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.131886","article-title":"C4BP-IgM protein as a therapeutic approach to treat Neisseria gonorrhoeae infections","volume":"4","author":"Bettoni","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.talanta.2026.130079_bib198","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/02713683.2022.2053725","article-title":"A Novel Full-Length Recombinant Human Complement Factor H (CFH; GEM103) for the Treatment of Age-Related Macular Degeneration Shows Similar In Vitro Functional Activity to Native CFH","volume":"47","author":"Biggs","year":"2022","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.talanta.2026.130079_bib199","article-title":"A Phase I, Single Ascending Dose Study of GEM103 (Recombinant Human Complement Factor H) in Patients with Geographic Atrophy, Ophthalmol","volume":"2","author":"Khanani","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.talanta.2026.130079_bib200","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2025.152989","article-title":"Moss-produced complement factor H (CPV-104) as a therapeutic regulator in complement-mediated diseases","volume":"230","author":"Dabrowska-Schlepp","year":"2025","journal-title":"Immunobiology"},{"key":"10.1016\/j.talanta.2026.130079_bib201","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1383123","article-title":"Moss-produced human complement factor H with modified glycans has an extended half-life and improved biological activity","volume":"15","author":"Tschongov","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib202","doi-asserted-by":"crossref","first-page":"866","DOI":"10.4049\/jimmunol.1501919","article-title":"Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H-like Protein 1 Reveal Functional Determinants of Complement Regulation","volume":"196","author":"Harder","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib203","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.4049\/jimmunol.1203548","article-title":"Rational engineering of a minimized immune inhibitor with unique triple-targeting properties","volume":"190","author":"Schmidt","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib204","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1182\/blood-2011-12-398792","article-title":"The complement receptor 2\/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment","volume":"119","author":"Risitano","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.talanta.2026.130079_bib205","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1182\/blood-2011-06-359646","article-title":"Design and development of TT30, a novel C3d-targeted C3\/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases","volume":"118","author":"Fridkis-Hareli","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.talanta.2026.130079_bib206","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2025.153011","article-title":"Regulation instead of inhibition: a triple fusion protein of complement regulators (TriFu) is superior in protecting animals in a rat xenotransfusion model when compared to C5-inhibition","volume":"230","author":"Savukoski","year":"2025","journal-title":"Immunobiology"},{"key":"10.1016\/j.talanta.2026.130079_bib207","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.105784","article-title":"Triple-fusion protein (TriFu): A potent, targeted, enzyme-like inhibitor of all three complement activation pathways","volume":"300","author":"Sonnentag","year":"2024","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.talanta.2026.130079_bib208","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.3324\/haematol.2013.089615","article-title":"Complement factor H-derived short consensus repeat 18-20 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells","volume":"98","author":"H\u00f6rl","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.talanta.2026.130079_bib209","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975676","article-title":"An optimized Factor H-Fc fusion protein against multidrug-resistant Neisseria gonorrhoeae","volume":"13","author":"Shaughnessy","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib210","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.4049\/jimmunol.1700426","article-title":"Factor H-IgG Chimeric Proteins as a Therapeutic Approach against the Gram-Positive Bacterial Pathogen Streptococcus pyogenes","volume":"199","author":"Blom","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib211","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2023-186453","article-title":"KP104, a Bifunctional C5 Antibody\/Factor H Fusion Protein, Effectively Controls Both Intravascular and Extravascular Hemolysis: Interim Results from a Phase 2 Study in Complement Inhibitor-Na\u00efve PNH Patients","volume":"142","author":"Zhang","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.talanta.2026.130079_bib212","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ymthe.2024.02.001","article-title":"C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement","volume":"32","author":"Liu","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.talanta.2026.130079_bib213","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1096\/fj.15-277103","article-title":"Genetically engineered fusion of MAP-1 and factor H domains 1-5 generates a potent dual upstream inhibitor of both the lectin and alternative complement pathways","volume":"29","author":"Nordmaj","year":"2015","journal-title":"FASEB J."},{"key":"10.1016\/j.talanta.2026.130079_bib214","doi-asserted-by":"crossref","first-page":"6598","DOI":"10.1096\/fj.201902475R","article-title":"A novel complement inhibitor sMAP-FH targeting both the lectin and alternative complement pathways","volume":"34","author":"Takasumi","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.talanta.2026.130079_bib215","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12974-024-03045-3","article-title":"Gliosis-dependent expression of complement factor H truncated variants attenuates retinal neurodegeneration following ischemic injury","volume":"21","author":"Biber","year":"2024","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.talanta.2026.130079_bib216","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1167\/tvst.12.7.17","article-title":"Regulatable Complement Inhibition of the Alternative Pathway Mitigates Wet Age-Related Macular Degeneration Pathology in a Mouse Model","volume":"12","author":"Parsons","year":"2023","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.talanta.2026.130079_bib217","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtm.2017.11.003","article-title":"Delivery of CR2-fH Using AAV Vector Therapy as Treatment Strategy in the Mouse Model of Choroidal Neovascularization","volume":"9","author":"Schnabolk","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.talanta.2026.130079_bib182","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.4049\/jimmunol.2000368","article-title":"Unraveling the Effect of a Potentiating Anti-Factor H Antibody on Atypical Hemolytic Uremic Syndrome-Associated Factor H Variants","volume":"205","author":"Dekkers","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib183","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1182\/bloodadvances.2018025692","article-title":"Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera","volume":"3","author":"Pouw","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.talanta.2026.130079_bib218","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41467-024-55092-2","article-title":"Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial","volume":"16","author":"Clarke","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.talanta.2026.130079_bib219","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1158\/1535-7163.MCT-22-0723","article-title":"Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103","volume":"22","author":"Bushey","year":"2023","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.talanta.2026.130079_bib220","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1681\/ASN.2017070738","article-title":"The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential","volume":"29","author":"Michelfelder","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.talanta.2026.130079_bib221","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s42003-022-03094-5","article-title":"A synthetic protein as efficient multitarget regulator against complement over-activation","volume":"5","author":"Ruiz-Molina","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.talanta.2026.130079_bib222","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1016\/j.xphs.2024.06.022","article-title":"Model-Based Interspecies Scaling for Predicting Human Pharmacokinetics of CB 4332, a Complement Factor I Protein","volume":"113","author":"Ayoun Alsoud","year":"2024","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.talanta.2026.130079_bib223","first-page":"293","article-title":"In vivo expression and efficacy following subretinal delivery of GT005, an investigational gene therapy for the treatment of geographic atrophy (GA)","volume":"63","author":"Stampoulis","year":"2022","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.talanta.2026.130079_bib224","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41434-021-00239-9","article-title":"Functional expression of complement factor I following AAV-mediated gene delivery in the retina of mice and human cells","volume":"28","author":"Dreismann","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.talanta.2026.130079_bib225","first-page":"2672","article-title":"A first in human study of Intravitreal (IVT) CLG561 in Subjects with Advanced Age-Related Macular Degeneration (AMD)","volume":"57","author":"Glazer","year":"2016","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.talanta.2026.130079_bib226","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/nbt1342","article-title":"Complement-targeted therapeutics","volume":"25","author":"Ricklin","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.talanta.2026.130079_bib181","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096371","article-title":"A novel antibody against human properdin inhibits the alternative complement system and specifically detects properdin from blood samples","volume":"9","author":"Pauly","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.talanta.2026.130079_bib227","doi-asserted-by":"crossref","first-page":"I83","DOI":"10.1161\/CIRCULATIONAHA.106.677914","article-title":"Beneficial effects of complement inhibition with soluble complement receptor 1 (TP10) during cardiac surgery: is there a gender difference?","volume":"116","author":"Lazar","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.talanta.2026.130079_bib228","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1586\/14779072.4.5.649","article-title":"The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass","volume":"4","author":"Li","year":"2006","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.talanta.2026.130079_bib229","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1600-0684.2007.00213.x","article-title":"Pre-clinical evaluation of an sLe x-glycosylated complement inhibitory protein in a non-human primate model of reperfused stroke","volume":"36","author":"Ducruet","year":"2007","journal-title":"J. Med. Primatol."},{"key":"10.1016\/j.talanta.2026.130079_bib230","doi-asserted-by":"crossref","first-page":"L1494","DOI":"10.1152\/ajplung.2001.281.6.L1494","article-title":"Sialyl Lewis(x) hybridized complement receptor type 1 moderates acid aspiration injury","volume":"281","author":"Kyriakides","year":"2001","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.talanta.2026.130079_bib231","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2024.117191","article-title":"Preclinical safety and efficacy of the recombinant CR1 drug product CSL040 in rats and cynomolgus monkeys","volume":"495","author":"Ruthsatz","year":"2025","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.talanta.2026.130079_bib232","doi-asserted-by":"crossref","first-page":"12723","DOI":"10.1096\/fj.201901643R","article-title":"Combining MAP-1:CD35 or MAP-1:CD55 fusion proteins with pattern-recognition molecules as novel targeted modulators of the complement cascade","volume":"33","author":"P\u00e9rez-Al\u00f3s","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.talanta.2026.130079_bib233","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-097029","volume":"15","author":"Kassimatis","year":"2025","journal-title":"BMJ Open"},{"key":"10.1016\/j.talanta.2026.130079_bib234","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13063-017-1972-x","article-title":"A double-blind randomised controlled investigation into the efficacy of Mirococept (APT070) for preventing ischaemia reperfusion injury in the kidney allograft (EMPIRIKAL): study protocol for a randomised controlled trial","volume":"18","author":"Kassimatis","year":"2017","journal-title":"Trials"},{"key":"10.1016\/j.talanta.2026.130079_bib235","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1365-2249.2007.03507.x","article-title":"Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack","volume":"150","author":"Zell","year":"2007","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib236","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.molonc.2013.02.011","article-title":"Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab","volume":"7","author":"Mamidi","year":"2013","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.talanta.2026.130079_bib237","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2174\/156800910793357952","article-title":"Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro","volume":"10","author":"Geis","year":"2010","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.talanta.2026.130079_bib238","doi-asserted-by":"crossref","first-page":"9953","DOI":"10.1073\/pnas.1818573116","article-title":"Molecular engineering of an efficient four-domain DAF-MCP chimera reveals the presence of functional modularity in RCA proteins","volume":"116","author":"Panwar","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.talanta.2026.130079_bib239","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/mus.24057","article-title":"Targeting therapy to the neuromuscular junction: proof of concept","volume":"49","author":"Kusner","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.talanta.2026.130079_bib240","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mus.23247","article-title":"Protective effect of scFv-DAF fusion protein on the complement attack to acetylcholine receptor: a possible option for treatment of myasthenia gravis","volume":"45","author":"Song","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.talanta.2026.130079_bib241","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/bjc.2012.132","article-title":"Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2\/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy","volume":"106","author":"Bellone","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.talanta.2026.130079_bib242","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clim.2015.05.006","article-title":"Complement receptor of the immunoglobulin superfamily reduces murine lupus nephritis and cutaneous disease","volume":"160","author":"Lieberman","year":"2015","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib243","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1084\/jem.20070432","article-title":"A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis","volume":"204","author":"Katschke","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib244","article-title":"A Targeted Complement Inhibitor CRIg\/FH Protects Against Experimental Autoimmune Myasthenia Gravis in Rats via Immune Modulation","volume":"13","author":"Song","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib245","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1182\/bloodadvances.2024012874","article-title":"CG001, a C3b-targeted complement inhibitor, blocks 3 complement pathways: development and preclinical evaluation","volume":"8","author":"Li","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.talanta.2026.130079_bib184","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.molimm.2018.06.001","article-title":"Complement analysis in the era of targeted therapeutics","volume":"102","author":"Proh\u00e1szka","year":"2018","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib185","article-title":"Novel immunochromatographic test for rapid detection of anti-factor H autoantibodies with an assessment of its clinical relevance","volume":"15","author":"Rodr\u00edguez de C\u00f3rdoba","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib186","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1537974","article-title":"Factor B as a therapeutic target for the treatment of complement-mediated diseases","volume":"16","author":"Kavanagh","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib246","first-page":"1262","article-title":"On the destruction of erythrocytes and other cells by antibody and complement","volume":"21","author":"Mayer","year":"1961","journal-title":"Cancer Res."},{"key":"10.1016\/j.talanta.2026.130079_bib247","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/ajcp\/79.1.65","article-title":"A study of optimal reaction conditions for an assay of the human alternative complement pathway","volume":"79","author":"Joiner","year":"1983","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.talanta.2026.130079_bib248","series-title":"Molecular basis of complement action","author":"Rapp","year":"1970"},{"key":"10.1016\/j.talanta.2026.130079_bib249","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0022-1759(84)90432-0","article-title":"Simplified assays of hemolytic activity of the classical and alternative complement pathways","volume":"72","author":"Nilsson","year":"1984","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.talanta.2026.130079_bib250","first-page":"161","article-title":"Screening for deficiencies in the classical and alternative pathways of complement by hemolysis in gel","volume":"89","author":"Truedsson","year":"1981","journal-title":"Acta Pathol. Microbiol. Scand. C"},{"key":"10.1016\/j.talanta.2026.130079_bib251","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJM193712022172307","article-title":"Chronic Hemolytic Anemia with Paroxysmal Nocturnal Hemoglobinuria","volume":"217","author":"Ham","year":"1937","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib252","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/blood.V35.4.462.462","article-title":"Diagnostic Specificity of Sucrose Hemolysis Test for Paroxysmal Nocturnal Hemoglobinuria","volume":"35","author":"Hartmann","year":"1970","journal-title":"Blood"},{"key":"10.1016\/j.talanta.2026.130079_bib253","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1172\/JCI105576","article-title":"Serum-red cell interactions at low ionic strength: erythrocyte complement coating and hemolysis of paroxysmal nocturnal hemoglobinuria cells","volume":"46","author":"Jenkins","year":"1967","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.talanta.2026.130079_bib254","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1365-2141.1973.tb01657.x","article-title":"Variations in the red cells in paroxysmal nocturnal haemoglobinuria","volume":"24","author":"Rosse","year":"1973","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.talanta.2026.130079_bib255","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1172\/JCI105389","article-title":"Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. II. The role of complement components in the increased sensitivity of PNH red cells to immune lysis","volume":"45","author":"Rosse","year":"1966","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.talanta.2026.130079_bib256","doi-asserted-by":"crossref","first-page":"9","DOI":"10.21307\/immunohematology-2019-497","article-title":"A gel microtyping system for diagnosis of paroxysmal nocturnal hemoglobinuria","volume":"18","author":"Zupanska","year":"2002","journal-title":"Immunohematol"},{"key":"10.1016\/j.talanta.2026.130079_bib257","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/10428199709058344","article-title":"Detection of \"PNH red cell\" populations in hematological disorders using the Sephacryl Gel Test micro typing system","volume":"28","author":"Meletis","year":"1997","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.talanta.2026.130079_bib258","first-page":"43","article-title":"A simplified assay for the specific diagnosis of paroxysmal nocturnal hemoglobinuria: detection of DAF(CD55)- and HRF20(CD59)- erythrocytes in microtyping cards","volume":"64","author":"Nilsson","year":"1993","journal-title":"Vox Sang."},{"key":"10.1016\/j.talanta.2026.130079_bib259","article-title":"Laboratory studies for paroxysmal nocturnal hemoglobinuria, with emphasis on flow cytometry","volume":"20","author":"Lima","year":"2020","journal-title":"Pract. Lab. Med."},{"issue":"Suppl 1","key":"10.1016\/j.talanta.2026.130079_bib260","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/ijlh.13011","article-title":"Sensitive and accurate identification of PNH clones based on ICCS\/ESCCA PNH Consensus Guidelines-A summary","volume":"41","author":"Illingworth","year":"2019","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.talanta.2026.130079_bib261","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ajh.23612","article-title":"Laboratory tests for paroxysmal nocturnal hemoglobinuria","volume":"89","author":"Preis","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.talanta.2026.130079_bib262","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1182\/blood-2015-02-629683","article-title":"Modified Ham test for atypical hemolytic uremic syndrome","volume":"125","author":"Gavriilaki","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.talanta.2026.130079_bib263","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1182\/blood-2023-190615","article-title":"The Bioluminescent Modified Ham Test Identifies the Classical Pathway As the Major Driver of Complement Activation in Atypical Hemolytic Uremic Syndrome and Primary Antiphospholipid Syndrome","volume":"142","author":"Cole","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.talanta.2026.130079_bib264","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/clinchem\/41.4.586","article-title":"Automated homogeneous liposome-based assay system for total complement activity","volume":"41","author":"Yamamoto","year":"1995","journal-title":"Clin. Chem."},{"key":"10.1016\/j.talanta.2026.130079_bib265","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0161-5890(02)00254-7","article-title":"Functional characterization of the lectin pathway of complement in human serum","volume":"39","author":"Roos","year":"2003","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib266","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0022-1759(01)00453-7","article-title":"An assay for the mannan-binding lectin pathway of complement activation","volume":"257","author":"Petersen","year":"2001","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.talanta.2026.130079_bib267","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0022-1759(93)90367-G","article-title":"New procedure for the detection of complement deficiency by ELISA. Analysis of activation pathways and circumvention of rheumatoid factor influence","volume":"166","author":"Fredrikson","year":"1993","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.talanta.2026.130079_bib268","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jim.2004.11.016","article-title":"Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA","volume":"296","author":"Seelen","year":"2005","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.talanta.2026.130079_bib269","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1365-2249.2011.04322.x","article-title":"Novel assays to assess the functional capacity of the classical, the alternative and the lectin pathways of the complement system","volume":"164","author":"Palarasah","year":"2011","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015443","article-title":"Functional analysis of Ficolin-3 mediated complement activation","volume":"5","author":"Hein","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.talanta.2026.130079_bib271","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1007\/s00216-025-05882-4","article-title":"A homogeneous immunoassay technology based on liposomes and the complement system enables one-step, no-wash, rapid diagnostics directly in serum","volume":"417","author":"Hoecherl","year":"2025","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.talanta.2026.130079_bib272","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1016\/j.ekir.2024.04.058","article-title":"A Cell-Based Assay to Measure the Activity of the Complement Convertases","volume":"9","author":"Stasi\u0142oj\u0107","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.talanta.2026.130079_bib273","doi-asserted-by":"crossref","DOI":"10.1002\/admi.202500350","article-title":"Assay System Based on Metabolic Glycoengineering\u2010Enabled Click Chemistry for the Efficient Evaluation of Complement\u2010Regulatory Peptide Coatings on Endothelial Cells","volume":"12","author":"Felsch","year":"2025","journal-title":"Adv. Mater. Interfac."},{"key":"10.1016\/j.talanta.2026.130079_bib274","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1182\/blood.2024025850","article-title":"Complement biosensors identify a classical pathway stimulus in complement-mediated thrombotic microangiopathy","volume":"144","author":"Cole","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.talanta.2026.130079_bib275","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.molimm.2019.08.002","article-title":"Complement deficiencies and dysregulation: Pathophysiological consequences, modern analysis, and clinical management","volume":"114","author":"Schr\u00f6der-Braunstein","year":"2019","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib276","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s10875-020-00754-1","article-title":"European Society for Immunodeficiencies (ESID) and European Reference Network on Rare Primary Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN RITA) Complement Guideline: Deficiencies, Diagnosis, and Management","volume":"40","author":"Brodszki","year":"2020","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib277","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.imbio.2016.06.008","article-title":"Complement analysis 2016: Clinical indications, laboratory diagnostics and quality control","volume":"221","author":"Proh\u00e1szka","year":"2016","journal-title":"Immunobiology"},{"key":"10.1016\/j.talanta.2026.130079_bib278","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/962702","article-title":"Complement diagnostics: concepts, indications, and practical guidelines","volume":"2012","author":"Nilsson","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib279","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0022-1759(72)90039-7","article-title":"Studies on single radial immunodiffusion techniques for the quantitation of antigen and antibody","volume":"1","author":"Jalanti","year":"1972","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.talanta.2026.130079_bib280","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0019-2791(65)90004-2","article-title":"Immunochemical quantitation of antigens by single radial immunodiffusion","volume":"2","author":"Mancini","year":"1965","journal-title":"Immunochemistry"},{"key":"10.1016\/j.talanta.2026.130079_bib281","first-page":"151","article-title":"Electroimmunodiffusion (EID): a simple, rapid method for quantitation of immunoglobulins in dilute biological fluids","volume":"69","author":"Merrill","year":"1967","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib282","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0003-2697(66)90246-6","article-title":"Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies","volume":"15","author":"Laurell","year":"1966","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.talanta.2026.130079_bib283","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.clinbiochem.2009.06.016","article-title":"Comparison of immunoturbidimetric and immunonephelometric assays for specific proteins","volume":"42","author":"Mali","year":"2009","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.talanta.2026.130079_bib284","first-page":"213","article-title":"Immunonephelometric and immunoturbidimetric assays for proteins","volume":"18","author":"Whicher","year":"1983","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.talanta.2026.130079_bib285","first-page":"982","article-title":"Modern complement analysis","volume":"10","author":"Kirschfink","year":"2003","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib286","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3389\/fimmu.2018.02237","article-title":"Interpretation of Serological Complement Biomarkers in Disease","volume":"9","author":"Ekdahl","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib287","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.addr.2011.05.010","article-title":"Advances in assay of complement function and activation","volume":"63","author":"Harboe","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.talanta.2026.130079_bib288","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2249.1993.tb05898.x","article-title":"Complement activation in septic baboons detected by neoepitope-specific assays for C3b\/iC3b\/C3c, C5a and the terminal C5b-9 complement complex (TCC)","volume":"91","author":"Mollnes","year":"1993","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib289","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.18632\/oncotarget.22963","article-title":"A novel multiplex detection array revealed systemic complement activation in oral squamous cell carcinoma","volume":"9","author":"Gallenkamp","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.talanta.2026.130079_bib290","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.molimm.2021.11.016","article-title":"Complement ratios C3bc\/C3 and sC5b-9\/C5 do not increase the sensitivity of detecting acute complement activation systemically","volume":"141","author":"Thomas","year":"2022","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib291","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0022-1759(84)90370-3","article-title":"Plasma C3d\/C3 quotient as a parameter for in vivo complement activation","volume":"74","author":"N\u00fcrnberger","year":"1984","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.talanta.2026.130079_bib292","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/art.40747","article-title":"Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity","volume":"71","author":"Kim","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.talanta.2026.130079_bib293","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/eci.12275","article-title":"C3 and C4 are strongly related to adipose tissue variables and cardiovascular risk factors","volume":"44","author":"Nilsson","year":"2014","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.talanta.2026.130079_bib294","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.molimm.2013.05.009","article-title":"Autoantibodies against complement components and functional consequences","volume":"56","author":"Dragon-Durey","year":"2013","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib295","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1036136","article-title":"Challenges in diagnostic testing of nephritic factors","volume":"13","author":"Michels","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib297","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/10408363.2021.1907297","article-title":"Complement testing in the clinical laboratory","volume":"58","author":"Willrich","year":"2021","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.talanta.2026.130079_bib298","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.tmrv.2019.09.001","article-title":"Clinical Complement Analysis-An Overview","volume":"33","author":"Skattum","year":"2019","journal-title":"Transfus. Med. Rev."},{"key":"10.1016\/j.talanta.2026.130079_bib299","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.molimm.2014.06.030","article-title":"Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach","volume":"61","author":"Grumach","year":"2014","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib296","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/ajh.24209","article-title":"Laboratory tests for disorders of complement and complement regulatory proteins","volume":"90","author":"Shih","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"Suppl 3","key":"10.1016\/j.talanta.2026.130079_bib300","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.1186\/ar586","article-title":"Complement and systemic lupus erythematosus","volume":"4","author":"Walport","year":"2002","journal-title":"Arthritis Res."},{"key":"10.1016\/j.talanta.2026.130079_bib301","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1279","article-title":"Autoantibodies against complement component C1q in systemic lupus erythematosus","volume":"10","author":"Trendelenburg","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib302","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2025.101060","article-title":"Hereditary angioedema diagnosis: Reflecting on the past, envisioning the future","volume":"18","author":"Grumach","year":"2025","journal-title":"World Allergy Organ. J."},{"key":"10.1016\/j.talanta.2026.130079_bib303","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1654078","article-title":"Evaluating functional C1INH with multiple laboratory methods across Hereditary Angioedema types","volume":"16","author":"Bardou","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib304","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107452","article-title":"Comprehensive functional characterization of complement factor I rare variant genotypes identified in the SCOPE geographic atrophy cohort","volume":"300","author":"Hallam","year":"2024","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.talanta.2026.130079_bib305","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1182\/blood.2021012037","article-title":"Functional characterization of 105 factor H variants associated with aHUS: lessons for variant classification","volume":"138","author":"Mart\u00edn Merinero","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.talanta.2026.130079_bib306","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 glomerulopathy - understanding a rare complement-driven renal disease","volume":"15","author":"Smith","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.talanta.2026.130079_bib307","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cytob.21111","article-title":"Use of CD157 in FLAER-based assays for high-sensitivity PNH granulocyte and PNH monocyte detection","volume":"86","author":"Sutherland","year":"2014","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.talanta.2026.130079_bib308","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1309\/AJCPMRDZZFQM7YJ4","article-title":"Use of a FLAER-based WBC assay in the primary screening of PNH clones","volume":"132","author":"Sutherland","year":"2009","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.talanta.2026.130079_bib309","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/cyto.b.20151","article-title":"Diagnosing PNH with FLAER and multiparameter flow cytometry","volume":"72","author":"Sutherland","year":"2007","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.talanta.2026.130079_bib310","first-page":"355","article-title":"Flow Cytometric Diagnosis of Paroxysmal Nocturnal Hemoglobinuria: Pearls and Pitfalls - A Critical Review Article","volume":"30","author":"Brando","year":"2019","journal-title":"EJIFCC"},{"key":"10.1016\/j.talanta.2026.130079_bib311","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1016\/j.molimm.2007.06.150","article-title":"Complement analysis in the 21st century","volume":"44","author":"Mollnes","year":"2007","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib312","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1093\/ndt\/gfy033","article-title":"Genetic analysis of the complement pathway in C3 glomerulopathy","volume":"33","author":"Zhao","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.talanta.2026.130079_bib313","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.4049\/jimmunol.1701695","article-title":"Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy","volume":"200","author":"Osborne","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib314","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.imbio.2016.05.002","article-title":"Chromosomal rearrangement-A rare cause of complement factor I associated atypical haemolytic uraemic syndrome","volume":"221","author":"Gleeson","year":"2016","journal-title":"Immunobiology"},{"key":"10.1016\/j.talanta.2026.130079_bib315","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12974-016-0548-0","article-title":"Multiallelic copy number variation in the complement component 4A (C4A) gene is associated with late-stage age-related macular degeneration (AMD)","volume":"13","author":"Grassmann","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.talanta.2026.130079_bib316","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/01.ASN.0000115702.28859.A7","article-title":"Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases","volume":"15","author":"Dragon-Durey","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.talanta.2026.130079_bib317","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ndt\/gfab218","article-title":"Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice","volume":"37","author":"Knoers","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.talanta.2026.130079_bib318","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1681\/ASN.2013050453","article-title":"Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome","volume":"25","author":"Bu","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.talanta.2026.130079_bib319","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12016-025-09027-4","article-title":"Hereditary Angioedema with Normal C1 Inhibitor: an Updated International Consensus Paper on Diagnosis, Pathophysiology, and Treatment","volume":"68","author":"Zuraw","year":"2025","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib320","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.785736","article-title":"Angioedema Without Wheals: Challenges in Laboratorial Diagnosis","volume":"12","author":"Grumach","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib321","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1681\/ASN.2019040433","article-title":"Large-Scale Whole-Genome Sequencing Reveals the Genetic Architecture of Primary Membranoproliferative GN and C3 Glomerulopathy","volume":"31","author":"Levine","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.talanta.2026.130079_bib322","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.1093\/hmg\/ddu226","article-title":"Whole-exome sequencing identifies rare, functional CFH variants in families with macular degeneration","volume":"23","author":"Yu","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.talanta.2026.130079_bib323","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1039765","article-title":"Distinction of early complement classical and lectin pathway activation via quantification of C1s\/C1-INH and MASP-1\/C1-INH complexes using novel ELISAs","volume":"13","author":"Hurler","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib324","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/all.15214","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.talanta.2026.130079_bib325","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2021.113109","article-title":"The crux of C1-INH testing in everyday lab work","volume":"497","author":"Sch\u00f6ffl","year":"2021","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.talanta.2026.130079_bib326","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1056\/NEJM196504012721301","article-title":"Detection of Hereditary Angioneutoric Edema by Demonstration of a Reduction in the Second Component of Human Complement","volume":"272","author":"Austen","year":"1965","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib327","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3181\/00379727-101-25034","article-title":"Assay and properties of serum inhibitor of C'l-esterase","volume":"101","author":"Levy","year":"1959","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib328","first-page":"147","article-title":"Quantification of C1-inhibitor functional activities by immunodiffusion assay in plasma of patients with hereditary angioedema--evidence of a functionally critical level of C1-inhibitor concentration","volume":"1","author":"Sp\u00e4th","year":"1984","journal-title":"Complement"},{"key":"10.1016\/j.talanta.2026.130079_bib329","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/0090-1229(80)90058-6","article-title":"Development of an immunochemical test to assess C1 inactivator function in human serum and its use for the diagnosis of hereditary angioedema","volume":"15","author":"Ziccardi","year":"1980","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/j.talanta.2026.130079_bib330","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106348","article-title":"Parallel comparison of three methodologies for measuring functional C1-inhibitor in Hereditary angioedema patients","volume":"81","author":"Kapoor","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.talanta.2026.130079_bib331","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jaip.2014.08.002","article-title":"Comparison of chromogenic and ELISA functional C1 inhibitor tests in diagnosing hereditary angioedema","volume":"3","author":"Li","year":"2015","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.talanta.2026.130079_bib332","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jim.2008.06.004","article-title":"Functional C1-inhibitor diagnostics in hereditary angioedema: assay evaluation and recommendations","volume":"338","author":"Wagenaar-Bos","year":"2008","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.talanta.2026.130079_bib333","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1258\/000456307779596020","article-title":"Laboratory testing for C1 inhibitor deficiency: a comparison of two approaches to C1 inhibitor function","volume":"44","author":"Gompels","year":"2007","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.talanta.2026.130079_bib334","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12317","article-title":"Application of a dried blood spot based proteomic and genetic assay for diagnosing hereditary angioedema","volume":"13","author":"Iura\u015fcu","year":"2023","journal-title":"Clin. Transl. Allergy"},{"key":"10.1016\/j.talanta.2026.130079_bib335","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113844","article-title":"A robust multiplexed assay to quantify C1-inhibitor, C1q, and C4 proteins for in vitro diagnosis of hereditary angioedema from dried blood spot","volume":"195","author":"Lai","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2026.130079_bib336","article-title":"Clinical validity of dried blood spot assay for the measurement of functional C1 inhibitor in angioedema due to C1 inhibitor deficiency","volume":"4","author":"Bernstein","year":"2025","journal-title":"J. Allergy Clin. Immunol. Glob."},{"key":"10.1016\/j.talanta.2026.130079_bib337","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cca.2020.02.010","article-title":"A novel functional C1 inhibitor activity assay in dried blood spot for diagnosis of Hereditary angioedema","volume":"504","author":"Lai","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.talanta.2026.130079_bib338","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106526","article-title":"A first of its kind quantitative functional C1-esterase inhibitor lateral flow assay for hereditary angioedema point-of-care diagnostic testing","volume":"83","author":"Chockalingam","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.talanta.2026.130079_bib339","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/all.12520","article-title":"A novel assay to diagnose hereditary angioedema utilizing inhibition of bradykinin-forming enzymes","volume":"70","author":"Joseph","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.talanta.2026.130079_bib340","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/all.12657","article-title":"C1 inhibitor function using contact-phase proteases as target: evaluation of an innovative assay","volume":"70","author":"Ghannam","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.talanta.2026.130079_bib341","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3389\/fimmu.2020.00794","article-title":"Patterns of C1-Inhibitor\/Plasma Serine Protease Complexes in Healthy Humans and in Hereditary Angioedema Patients","volume":"11","author":"Kajd\u00e1csi","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib342","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1002\/eji.201243196","article-title":"Analysis of genes coding for CD46, CD55, and C4b-binding protein in patients with idiopathic, recurrent, spontaneous pregnancy loss","volume":"43","author":"Mohlin","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib343","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2249.2008.03798.x","article-title":"Lack of association between polymorphisms in C4b-binding protein and atypical haemolytic uraemic syndrome in the Spanish population","volume":"155","author":"Mart\u00ednez-Barricarte","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib344","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.4049\/jimmunol.180.9.6385","article-title":"A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity","volume":"180","author":"Blom","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib345","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.imlet.2015.11.014","article-title":"C4b-binding protein: The good, the bad and the deadly. Novel functions of an old friend","volume":"169","author":"Ermert","year":"2016","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.talanta.2026.130079_bib346","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1073\/pnas.80.11.3461","article-title":"Visualization of human C4b-binding protein and its complexes with vitamin K-dependent protein S and complement protein C4b","volume":"80","author":"Dahlb\u00e4ck","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.talanta.2026.130079_bib347","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1042\/bj2090857","article-title":"Degradation of human complement component C4b in the presence of the C4b-binding protein-protein S complex","volume":"209","author":"Dahlb\u00e4ck","year":"1983","journal-title":"Biochem. J."},{"key":"10.1016\/j.talanta.2026.130079_bib348","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1042\/bj2090847","article-title":"Purification of human C4b-binding protein and formation of its complex with vitamin K-dependent protein S","volume":"209","author":"Dahlb\u00e4ck","year":"1983","journal-title":"Biochem. J."},{"key":"10.1016\/j.talanta.2026.130079_bib349","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/00365519509089605","article-title":"An automated C4b binding protein assay compared with an electroimmunoassay in a clinical material","volume":"55","author":"Dahlberg","year":"1995","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.talanta.2026.130079_bib350","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jvs.2008.12.033","article-title":"Complement activation and plasma levels of C4b-binding protein in critical limb ischemia patients","volume":"50","author":"Martin","year":"2009","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.talanta.2026.130079_bib351","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0009-8981(94)05988-5","article-title":"One-step sandwich enzyme immunoassays for human C4b-binding protein (C4BP) and protein S-C4BP complex using monoclonal antibodies","volume":"234","author":"Tamei","year":"1995","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.talanta.2026.130079_bib352","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-1-62703-724-2_14","article-title":"Purification and functional characterization of C4b-binding protein (C4BP)","volume":"1100","author":"Mohlin","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.talanta.2026.130079_bib353","doi-asserted-by":"crossref","first-page":"27136","DOI":"10.1074\/jbc.M102445200","article-title":"Structural requirements for the complement regulatory activities of C4BP","volume":"276","author":"Blom","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.talanta.2026.130079_bib354","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1002\/1521-4141(200109)31:9<2771::AID-IMMU2771>3.0.CO;2-0","article-title":"Bordetella pertussis binds to human C4b-binding protein (C4BP) at a site similar to that used by the natural ligand C4b","volume":"31","author":"Bergg\u00e5rd","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib355","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1084\/jem.20050189","article-title":"C4b-binding protein binds to necrotic cells and DNA, limiting DNA release and inhibiting complement activation","volume":"201","author":"Trouw","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib356","doi-asserted-by":"crossref","first-page":"18333","DOI":"10.1074\/jbc.M114.619494","article-title":"A Novel Interaction between Complement Inhibitor C4b-binding Protein and Plasminogen That Enhances Plasminogen Activation","volume":"290","author":"Agarwal","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.talanta.2026.130079_bib357","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1074-7613(03)00149-3","article-title":"C4b-binding protein (C4BP) activates B cells through the CD40 receptor","volume":"18","author":"Brodeur","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.talanta.2026.130079_bib358","doi-asserted-by":"crossref","first-page":"23869","DOI":"10.1074\/jbc.C400159200","article-title":"The C4b-binding protein-protein S complex inhibits the phagocytosis of apoptotic cells","volume":"279","author":"Kask","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.talanta.2026.130079_bib359","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1007\/s00216-012-6603-5","article-title":"Improved detection specificity for plasma proteins by targeting cysteine-containing peptides with photo-SRM","volume":"405","author":"Enjalbert","year":"2013","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.talanta.2026.130079_bib360","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1038\/s44318-024-00128-y","article-title":"Higher-order structure and proteoforms of co-occurring C4b-binding protein assemblies in human serum","volume":"43","author":"Kadav\u00e1","year":"2024","journal-title":"EMBO J."},{"key":"10.1016\/j.talanta.2026.130079_bib361","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.molimm.2004.02.005","article-title":"The human complement factor H: functional roles, genetic variations and disease associations","volume":"41","author":"Rodr\u00edguez de C\u00f3rdoba","year":"2004","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib362","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.molimm.2022.08.010","article-title":"Evaluating the clinical utility of measuring levels of factor H and the related proteins","volume":"151","author":"Banerjee","year":"2022","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib363","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jim.2010.12.020","article-title":"Alternative complement pathway assessment in patients with atypical HUS","volume":"365","author":"Roumenina","year":"2011","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.talanta.2026.130079_bib364","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1042\/bj2320841","article-title":"Structural and functional analysis of the complement component factor H with the use of different enzymes and monoclonal antibodies to factor H","volume":"232","author":"Alsenz","year":"1985","journal-title":"Biochem. J."},{"key":"10.1016\/j.talanta.2026.130079_bib365","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1084\/jem.122.2.277","article-title":"Isolation of Beta IF-Globulin from Human Serum and its Characterization as the Fifth Component of Complement","volume":"122","author":"Nilsson","year":"1965","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib366","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2143\/ACB.68.1.2062713","article-title":"Complement factor H functional assay may help to monitor atypical haemolytic uraemic syndrome: a pilot study","volume":"68","author":"Massart","year":"2013","journal-title":"Acta Clin. Belg."},{"key":"10.1016\/j.talanta.2026.130079_bib367","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4049\/jimmunol.122.1.75","article-title":"Human Alternative Complement Pathway: Membrane-Associated Sialic Acid Regulates the Competition between B and \u03b21H for Cell-Bound C3b","volume":"122","author":"Kazatchkine","year":"1979","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib368","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.molimm.2004.01.003","article-title":"Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H","volume":"41","author":"S\u00e1nchez-Corral","year":"2004","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib369","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.4049\/jimmunol.169.9.4702","article-title":"Cutting edge: localization of the host recognition functions of complement factor H at the carboxyl-terminal: implications for hemolytic uremic syndrome","volume":"169","author":"Pangburn","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib370","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-1-0716-1016-9_7","article-title":"Hemolytic Tests Exploring Factor H Functional Activities","volume":"2227","author":"Chabannes","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.talanta.2026.130079_bib371","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.molimm.2013.11.021","article-title":"An ELISA assay with two monoclonal antibodies allows the estimation of free factor H and identifies patients with acquired deficiency of this complement regulator","volume":"58","author":"Nozal","year":"2014","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib372","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.3389\/fimmu.2019.01282","article-title":"Clinical and Immunological Profile of Anti-factor H Antibody Associated Atypical Hemolytic Uremic Syndrome: A Nationwide Database","volume":"10","author":"Puraswani","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib373","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/ki.2010.275","article-title":"Variant-specific quantification of factor H in plasma identifies null alleles associated with atypical hemolytic uremic syndrome","volume":"78","author":"Hakobyan","year":"2010","journal-title":"Kidney Int."},{"key":"10.1016\/j.talanta.2026.130079_bib374","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1167\/iovs.07-1523","article-title":"Measurement of factor H variants in plasma using variant-specific monoclonal antibodies: application to assessing risk of age-related macular degeneration","volume":"49","author":"Hakobyan","year":"2008","journal-title":"Invest. Ophthalmol. Vis."},{"key":"10.1016\/j.talanta.2026.130079_bib375","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fimmu.2014.00126","article-title":"Molecular Interactions between Complement Factor H and Its Heparin and Heparan Sulfate Ligands","volume":"5","author":"Perkins","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib376","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.imbio.2011.10.003","article-title":"Complement factor H-ligand interactions: self-association, multivalency and dissociation constants","volume":"217","author":"Perkins","year":"2012","journal-title":"Immunobiology"},{"key":"10.1016\/j.talanta.2026.130079_bib377","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.4049\/jimmunol.1201751","article-title":"Tissue-specific host recognition by complement factor H is mediated by differential activities of its glycosaminoglycan-binding regions","volume":"190","author":"Clark","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib378","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nchembio.1696","article-title":"Structural basis for sialic acid-mediated self-recognition by complement factor H","volume":"11","author":"Blaum","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.talanta.2026.130079_bib379","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.201600237","article-title":"A novel, multiplexed targeted mass spectrometry assay for quantification of complement factor H (CFH) variants and CFH-related proteins 1-5 in human plasma","volume":"17","author":"Zhang","year":"2017","journal-title":"Proteomics"},{"key":"10.1016\/j.talanta.2026.130079_bib380","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1515\/cclm-2014-0920","article-title":"Novel association of FCGR2A polymorphism with age-related macular degeneration (AMD) and development of a novel CFH real-time genotyping method","volume":"53","author":"Velissari","year":"2015","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib381","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.kint.2017.07.015","article-title":"Complete functional characterization of disease-associated genetic variants in the complement factor H gene","volume":"93","author":"Merinero","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.talanta.2026.130079_bib382","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.660194","article-title":"A Family Affair: Addressing the Challenges of Factor H and the Related Proteins","volume":"12","author":"Poppelaars","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib383","doi-asserted-by":"crossref","DOI":"10.1159\/000545139","article-title":"Development and characterization of novel ELISAs for the specific quantification of the factor H-related proteins 2, 3, 4 and 5","author":"van Rossum","year":"2025","journal-title":"J. Innate Immun."},{"key":"10.1016\/j.talanta.2026.130079_bib384","article-title":"Complement Factor I Variants in Complement-Mediated Renal Diseases","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib385","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1093\/hmg\/ddac103","article-title":"Functional analysis of rare genetic variants in complement factor I in advanced age-related macular degeneration","volume":"31","author":"Java","year":"2022","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.talanta.2026.130079_bib386","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1084\/jem.146.1.257","article-title":"Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution","volume":"146","author":"Pangburn","year":"1977","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib387","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1084\/jem.141.5.1221","article-title":"The mechanism of action of the C3b inactivator (conglutinogen-activating factor) on its naturally occurring substrate, the major fragment of the third component of complement (C3b)","volume":"141","author":"Gitlin","year":"1975","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib388","doi-asserted-by":"crossref","first-page":"691","DOI":"10.4049\/jimmunol.100.4.691","article-title":"The Demonstration in Human Serum of \u201cConglutinogen-Activating Factor\u201d and its Effect on the Third Component of Complement","volume":"100","author":"Lachmann","year":"1968","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib389","series-title":"Fibrinolysis, and Nonmammalian Blood Coagulation Factors and Inhibitors","first-page":"13","article-title":"Complement factor I and cofactors in control of complement system convertase enzymes, in: Methods in Enzymology Proteolytic Enzymes in Coagulation, Fibrinolysis, and Complement Activation Part B: Complement Activation","author":"Sim","year":"1993"},{"key":"10.1016\/j.talanta.2026.130079_bib390","series-title":"Fibrinolysis, and Nonmammalian Blood Coagulation Factors and Inhibitors","first-page":"112","article-title":"C3b inactivator and \u03b21H, in: Methods in Enzymology Proteolytic Enzymes in Coagulation, Fibrinolysis, and Complement Activation Part B: Complement Activation","author":"Gail Crossley","year":"1993"},{"key":"10.1016\/j.talanta.2026.130079_bib391","series-title":"Methods in Enzymology Proteolytic Enzymes in Coagulation, Fibrinolysis, and Complement Activation Part B: Complement Activation, Fibrinolysis, and Nonmammalian Blood Coagulation Factors and Inhibitors","first-page":"639","article-title":"Alternative pathway of complement","author":"Pangburn","year":"1993"},{"key":"10.1016\/j.talanta.2026.130079_bib392","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2007.05.004","article-title":"Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome","volume":"45","author":"Kavanagh","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib393","doi-asserted-by":"crossref","first-page":"6235","DOI":"10.1074\/jbc.M109.097212","article-title":"Analysis of binding sites on complement factor I that are required for its activity","volume":"285","author":"Nilsson","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.talanta.2026.130079_bib394","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/eji.200838702","article-title":"Genetic, molecular and functional analyses of complement factor I deficiency","volume":"39","author":"Nilsson","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib395","doi-asserted-by":"crossref","first-page":"12839","DOI":"10.1073\/pnas.1102167108","article-title":"Structural basis for complement factor I control and its disease-associated sequence polymorphisms","volume":"108","author":"Roversi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.talanta.2026.130079_bib396","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1279612","article-title":"Functional evaluation of complement factor I variants by immunoassays and SDS-PAGE","volume":"14","author":"Gerogianni","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib397","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1167\/tvst.9.9.37","article-title":"Functional Analysis of Rare Genetic Variants in Complement Factor I (CFI) using a Serum-Based Assay in Advanced Age-related Macular Degeneration","volume":"9","author":"Java","year":"2020","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.talanta.2026.130079_bib398","article-title":"Functional Analysis of Variants in Complement Factor I Identified in Age-Related Macular Degeneration and Atypical Hemolytic Uremic Syndrome","volume":"12","author":"de Jong","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib399","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jim.2018.03.013","article-title":"A novel and sensitive functional assay for complement Factor I based on the third proteolytic clip of C3b","volume":"457","author":"Lachmann","year":"2018","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.talanta.2026.130079_bib400","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1028760","article-title":"A novel method for real-time analysis of the complement C3b:FH:FI complex reveals dominant negative CFI variants in age-related macular degeneration","volume":"13","author":"Hallam","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib401","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1446081","article-title":"Functional evaluation of rare variants in complement factor I using a minigene assay","volume":"15","author":"Donelson","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib402","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1167\/iovs.16-20867","article-title":"Systematic Functional Testing of Rare Variants: Contributions of CFI to Age-Related Macular Degeneration","volume":"58","author":"Tan","year":"2017","journal-title":"Invest. Ophthalmol. Vis."},{"key":"10.1016\/j.talanta.2026.130079_bib403","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s00467-018-4042-z","article-title":"The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?","volume":"34","author":"Michels","year":"2019","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.talanta.2026.130079_bib404","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1699-0463.1990.tb05008.x","article-title":"Inherited complement deficiency states: implications for immunity and immunological disease","volume":"98","author":"Sj\u00f6holm","year":"1990","journal-title":"APMIS"},{"key":"10.1016\/j.talanta.2026.130079_bib405","first-page":"291","article-title":"Properdin deficiency in a family with fulminant meningococcal infections","volume":"50","author":"Sj\u00f6holm","year":"1982","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib406","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0161-5890(99)00107-8","article-title":"Properdin deficiency: molecular basis and disease association","volume":"36","author":"Fijen","year":"1999","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib407","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1046\/j.1365-2249.1999.01057.x","article-title":"Properdin deficiency and meningococcal disease--identifying those most at risk","volume":"118","author":"Linton","year":"1999","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib408","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1126\/science.120.3112.279","article-title":"The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena","volume":"120","author":"Pillemer","year":"1954","journal-title":"Science"},{"key":"10.1016\/j.talanta.2026.130079_bib409","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4049\/jimmunol.100.1.142","article-title":"Properties of Highly Purified Human Properdin","volume":"100","author":"Pensky","year":"1968","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1084\/jem.103.1.1.1","article-title":"The properdin system and immunity. III. The zymosan assay of properdin","volume":"103","author":"Pillemer","year":"1956","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib411","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0019-2791(73)90082-7","article-title":"Solid phase radioimmunoassay of properdin","volume":"10","author":"Minta","year":"1973","journal-title":"Immunochemistry"},{"key":"10.1016\/j.talanta.2026.130079_bib412","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0022-1759(78)90175-8","article-title":"A radial hemolysis method in agarose for the functional assay of properdin","volume":"19","author":"Minta","year":"1978","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.talanta.2026.130079_bib413","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0022-1759(87)90001-9","article-title":"A sandwich ELISA for properdin in clinical specimens","volume":"98","author":"Hoffmann","year":"1987","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.talanta.2026.130079_bib414","doi-asserted-by":"crossref","first-page":"602","DOI":"10.4049\/jimmunol.124.2.602","article-title":"Native and activated properdin: interconvertibility and identity of amino- and carboxy-terminal sequences","volume":"124","author":"Medicus","year":"1980","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib415","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1084\/jem.142.4.856","article-title":"Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase","volume":"142","author":"Fearon","year":"1975","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib416","series-title":"Fibrinolysis, and Nonmammalian Blood Coagulation Factors and Inhibitors","first-page":"143","article-title":"Preparation of human properdin, in: Methods in Enzymology Proteolytic Enzymes in Coagulation, Fibrinolysis, and Complement Activation Part B: Complement Activation","author":"Reid","year":"1993"},{"key":"10.1016\/j.talanta.2026.130079_bib417","article-title":"A novel assay that characterizes properdin function shows neutrophil-derived properdin has a distinct oligomeric distribution","volume":"13","author":"Moore","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib418","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0161-5890(00)00047-X","article-title":"Inhibition of complement alternative pathway function with anti-properdin monoclonal antibodies","volume":"37","author":"Gupta-Bansal","year":"2000","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib419","doi-asserted-by":"crossref","first-page":"ofw250","DOI":"10.1093\/ofid\/ofw250","article-title":"Properdin Levels in Individuals with Chemotherapy-Induced Neutropenia","volume":"4","author":"Tsyrkunou","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.talanta.2026.130079_bib420","doi-asserted-by":"crossref","first-page":"13504","DOI":"10.1073\/pnas.1309618110","article-title":"Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin","volume":"110","author":"Alcorlo","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.talanta.2026.130079_bib421","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.15252\/embj.201696173","article-title":"Functional and structural insight into properdin control of complement alternative pathway amplification","volume":"36","author":"Pedersen","year":"2017","journal-title":"EMBO J."},{"key":"10.1016\/j.talanta.2026.130079_bib422","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3389\/fimmu.2018.00612","article-title":"Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases","volume":"9","author":"Michels","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib423","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/cei.12388","article-title":"A novel method for direct measurement of complement convertases activity in human serum","volume":"178","author":"Blom","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib424","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-1-0716-1016-9_8","article-title":"Functional Hemolytic Test for Complement Alternative Pathway Convertase Activity","volume":"2227","author":"Michels","year":"2021","journal-title":"The Complement Syst."},{"key":"10.1016\/j.talanta.2026.130079_bib425","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3389\/fimmu.2019.01350","article-title":"Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy","volume":"10","author":"Michels","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib426","article-title":"Hereditary angioedema with normal C1 inhibitor associated with carboxypeptidase N deficiency","volume":"3","author":"Vincent","year":"2024","journal-title":"J. Allergy Clin. Immunol. Glob."},{"key":"10.1016\/j.talanta.2026.130079_bib427","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cca.2006.02.035","article-title":"A rapid and sensitive assay for the quantitation of carboxypeptidase N, an important regulator of inflammation","volume":"371","author":"Willemse","year":"2006","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.talanta.2026.130079_bib428","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/0006-2952(67)90159-1","article-title":"Carboxypeptidase in blood and other fluids. 3. The esterase activity of the enzyme","volume":"16","author":"Erd\u00f6s","year":"1967","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.talanta.2026.130079_bib429","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/0006-2952(64)90033-4","article-title":"Carboxypeptidase in blood and other fluids. I. Properties, distribution, and partial purification of the enzyme","volume":"13","author":"Erd\u00f6s","year":"1964","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.talanta.2026.130079_bib430","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0006-2952(62)90119-3","article-title":"An enzyme in human blood plasma that inactivates bradykinin and kallidins","volume":"11","author":"Erd\u00f6s","year":"1962","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.talanta.2026.130079_bib431","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1084\/jem.129.5.1109","article-title":"Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum","volume":"129","author":"Bokisch","year":"1969","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib432","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/0003-2697(80)90598-9","article-title":"An improved spectrophotometric assay for human plasma carboxypeptidase N1","volume":"108","author":"Plummer","year":"1980","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.talanta.2026.130079_bib433","first-page":"605","article-title":"A simple spectrophotometric assay of carboxypeptidase N (kininase I) in human serum","volume":"21","author":"Schweisfurth","year":"1983","journal-title":"J. Clin. Chem. Clin. Biochem."},{"key":"10.1016\/j.talanta.2026.130079_bib434","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1093\/clinchem\/31.12.1936","article-title":"Assay of carboxypeptidase N activity in serum by liquid-chromatographic determination of hippuric acid","volume":"31","author":"Hendriks","year":"1985","journal-title":"Clin. Chem."},{"key":"10.1016\/j.talanta.2026.130079_bib435","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0021-9673(01)90890-8","article-title":"Rapid assay of human plasma carboxypeptidase N by high-performance liquid chromatographic separation of hippuryl-lysine and its product","volume":"266","author":"Marceau","year":"1983","journal-title":"J. Chromatogr."},{"key":"10.1016\/j.talanta.2026.130079_bib436","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0003-2697(87)90372-1","article-title":"Carboxypeptidase N: colorimetric assay using a new substrate","volume":"164","author":"Hendriks","year":"1987","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.talanta.2026.130079_bib437","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0009-8981(86)90323-2","article-title":"Colorimetric assay for carboxypeptidase N in serum","volume":"157","author":"Hendriks","year":"1986","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.talanta.2026.130079_bib438","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cca.2007.09.013","article-title":"Comparative substrate specificity study of carboxypeptidase U (TAFIa) and carboxypeptidase N: development of highly selective CPU substrates as useful tools for assay development","volume":"387","author":"Willemse","year":"2008","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.talanta.2026.130079_bib439","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ab.2006.05.020","article-title":"The intrinsic enzymatic activity of plasma procarboxypeptidase U (TAFI) can interfere with plasma carboxypeptidase N assays","volume":"356","author":"Willemse","year":"2006","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.talanta.2026.130079_bib440","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/jcp.46.11.1042","article-title":"Quantitation of vitronectin in serum: evaluation of its usefulness in routine clinical practice","volume":"46","author":"Boyd","year":"1993","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.talanta.2026.130079_bib441","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics12123010","article-title":"Clusterin Plasma Concentrations Are Decreased in Sepsis and Inversely Correlated with Established Markers of Inflammation","volume":"12","author":"Yagmur","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.talanta.2026.130079_bib442","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/toxsci\/kfae088","article-title":"Qualified kidney injury biomarkers demonstrate value during early clinical drug development","volume":"201","author":"Ravindra","year":"2024","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.talanta.2026.130079_bib443","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90973-2","article-title":"Clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response","volume":"11","author":"Krop\u00e1\u010dkov\u00e1","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.talanta.2026.130079_bib444","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8814841","article-title":"Serum Clusterin: A Potential Marker for Assessing the Clinical Severity and Short-Term Prognosis of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure","volume":"2020","author":"Liu","year":"2020","journal-title":"Dis. Markers"},{"key":"10.1016\/j.talanta.2026.130079_bib445","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2337\/dc11-1491","article-title":"Novel urinary protein biomarkers predicting the development of microalbuminuria and renal function decline in type 1 diabetes","volume":"35","author":"Schlatzer","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.talanta.2026.130079_bib446","doi-asserted-by":"crossref","first-page":"31","DOI":"10.21037\/tcr-22-1882","article-title":"Clusterin is a biomarker of breast cancer prognosis and correlated with immune microenvironment","volume":"12","author":"Yang","year":"2023","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.talanta.2026.130079_bib447","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.clinbiochem.2012.04.024","article-title":"Clinical significance of serum clusterin as a biomarker for evaluating diagnosis and metastasis potential of viral-related hepatocellular carcinoma","volume":"45","author":"Nafee","year":"2012","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.talanta.2026.130079_bib448","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/623190","article-title":"The application of a three-step serum proteome analysis for the discovery and identification of novel biomarkers of hepatocellular carcinoma","volume":"2012","author":"Kimura","year":"2012","journal-title":"Int. J. Proteomics"},{"key":"10.1016\/j.talanta.2026.130079_bib449","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1097\/01.MP.0000036386.87517.AA","article-title":"Clusterin expression in malignant lymphomas: a survey of 266 cases","volume":"15","author":"Saffer","year":"2002","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.talanta.2026.130079_bib450","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.13281","article-title":"Brain and plasmatic CLUSTERIN are translational markers of Alzheimer's disease","volume":"35","author":"Tournier","year":"2025","journal-title":"Brain Pathol."},{"key":"10.1016\/j.talanta.2026.130079_bib451","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026032","article-title":"Apolipoprotein J\/Clusterin is a novel structural component of human erythrocytes and a biomarker of cellular stress and senescence","volume":"6","author":"Antonelou","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.talanta.2026.130079_bib452","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13058-025-02053-2","article-title":"Identification of vitronectin as a potential non-invasive biomarker of metastatic breast cancer using a label-free LC-MS\/MS approach","volume":"27","author":"Roy","year":"2025","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.talanta.2026.130079_bib453","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3233\/CBM-160639","article-title":"Diagnostic and prognostic roles of serum vitronectin in hepatitis B-related hepatocellular carcinoma","volume":"17","author":"Yang","year":"2016","journal-title":"Cancer Biomarkers"},{"key":"10.1016\/j.talanta.2026.130079_bib454","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/liv.12277","article-title":"Identification of candidate biomarkers for hepatocellular carcinoma in plasma of HCV-infected cirrhotic patients by 2-D DIGE","volume":"34","author":"Ferr\u00edn","year":"2014","journal-title":"Liver Int."},{"key":"10.1016\/j.talanta.2026.130079_bib455","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1186\/s12967-024-05777-5","article-title":"Towards clinical translation of urinary vitronectin for non-invasive detection and monitoring of renal fibrosis in kidney transplant patients","volume":"22","author":"Clos-Sansalvador","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib456","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s40620-020-00886-y","article-title":"Urinary vitronectin identifies patients with high levels of fibrosis in kidney grafts","volume":"34","author":"Carreras-Planella","year":"2021","journal-title":"J. Nephrol."},{"key":"10.1016\/j.talanta.2026.130079_bib457","article-title":"Serum proteomics identify biomarkers and pathogenesis of portopulmonary hypertension diagnosed based on echocardiography","volume":"15","author":"Du","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.talanta.2026.130079_bib458","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0022-1759(90)90186-Y","article-title":"Sandwich ELISA assay for quantitative measurement of SP-40,40 in seminal plasma and serum","volume":"131","author":"Choi","year":"1990","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.talanta.2026.130079_bib459","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0165-022X(00)00137-8","article-title":"An antigen capture assay for the measurement of serum clusterin concentrations","volume":"48","author":"Morrissey","year":"2001","journal-title":"J. Biochem. Biophys. Methods"},{"key":"10.1016\/j.talanta.2026.130079_bib460","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1177\/0004563213503456","article-title":"Quantification of clusterin in paired cerebrospinal fluid and plasma samples","volume":"51","author":"Jongbloed","year":"2014","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.talanta.2026.130079_bib461","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/bju.14978","article-title":"Non-radiological assessment of kidney stones using the kidney injury test (KIT), a spot urine assay","volume":"125","author":"Yang","year":"2020","journal-title":"BJU Int."},{"key":"10.1016\/j.talanta.2026.130079_bib462","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba2501","article-title":"A urine score for noninvasive accurate diagnosis and prediction of kidney transplant rejection","volume":"12","author":"Yang","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib463","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20184463","article-title":"Noninvasive Urinary Monitoring of Progression in IgA Nephropathy","volume":"20","author":"Yang","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.talanta.2026.130079_bib464","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8040499","article-title":"A Novel Multi-Biomarker Assay for Non-Invasive Quantitative Monitoring of Kidney Injury","volume":"8","author":"Watson","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib465","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.ekir.2025.04.035","article-title":"Urinary Clusterin is a Biomarker of Renal Epithelial Senescence and Predicts Human Kidney Disease Progression","volume":"10","author":"Baird","year":"2025","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.talanta.2026.130079_bib466","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1477-5956-7-15","article-title":"Development of reverse phase protein microarrays for the validation of clusterin, a mid-abundant blood biomarker","volume":"7","author":"Aguilar-Mahecha","year":"2009","journal-title":"Proteome Sci."},{"key":"10.1016\/j.talanta.2026.130079_bib467","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M110.004978","article-title":"Multiplexed homogeneous proximity ligation assays for high-throughput protein biomarker research in serological material","volume":"10","author":"Lundberg","year":"2011","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.talanta.2026.130079_bib468","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1750-1326-7-41","article-title":"Mass spectrometry quantification of clusterin in the human brain","volume":"7","author":"Chen","year":"2012","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.talanta.2026.130079_bib469","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.202200072","article-title":"Developing quantitative assays for six urinary glycoproteins using parallel reaction monitoring, data-independent acquisition, and TMT-based data-dependent acquisition","volume":"23","author":"Ponce","year":"2023","journal-title":"Proteomics"},{"key":"10.1016\/j.talanta.2026.130079_bib470","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0022-1759(93)90014-X","article-title":"Quantitation of vitronectin and clusterin. Pitfalls and solutions in enzyme immunoassays for adhesive proteins","volume":"160","author":"H\u00f8g\u00e5sen","year":"1993","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.talanta.2026.130079_bib471","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/blood.V72.1.185.bloodjournal721185","article-title":"Plasma vitronectin polymorphism in normal subjects and patients with disseminated intravascular coagulation","volume":"72","author":"Conlan","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.talanta.2026.130079_bib472","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1600-0609.1987.tb00747.x","article-title":"S protein\/vitronectin in chronic liver diseases: correlations with serum cholinesterase, coagulation factor X and complement component C3","volume":"39","author":"Kemkes-Matthes","year":"1987","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.talanta.2026.130079_bib473","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/0003-2697(90)90608-C","article-title":"An enzymatic assay for vitronectin based on its selective phosphorylation by protein kinase A","volume":"188","author":"Korc-Grodzicki","year":"1990","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.talanta.2026.130079_bib474","first-page":"99","article-title":"Building a novel vitronectin assay by immobilization of integrin on calixarene monolayer","volume":"75","author":"Chen","year":"2008","journal-title":"Talanta"},{"key":"10.1016\/j.talanta.2026.130079_bib475","doi-asserted-by":"crossref","DOI":"10.1002\/bies.70091","article-title":"Flow Cytometry: Advances, Challenges and Trends","volume":"48","author":"Robinson","year":"2026","journal-title":"Bioessays"},{"key":"10.1016\/j.talanta.2026.130079_bib476","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/cyto.a.24566","article-title":"The evolution of spectral flow cytometry","volume":"101","author":"Nolan","year":"2022","journal-title":"Cytometry A"},{"key":"10.1016\/j.talanta.2026.130079_bib477","first-page":"13.4.1","article-title":"Assays for membrane complement receptors","volume":"13","author":"O'Rear","year":"2001","journal-title":"Curr. Protoc. Immunol. Chapter"},{"key":"10.1016\/j.talanta.2026.130079_bib478","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0165-022X(95)00005-C","article-title":"Rapid purification of human complement receptor type 1 (CD35, CR1)","volume":"32","author":"Seya","year":"1996","journal-title":"J. Biochem. Biophys. Methods"},{"key":"10.1016\/j.talanta.2026.130079_bib479","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0022-1759(91)90291-M","article-title":"A flow cytometric assay for measuring complement receptor 1 (CR1) and the complement fragments C3d and C4d on erythrocytes","volume":"142","author":"Freysdottir","year":"1991","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.talanta.2026.130079_bib480","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/978-1-62703-724-2_27","article-title":"Detection of cell membrane-bound CD46 using flow cytometry","volume":"1100","author":"Kolev","year":"2014","journal-title":"The Complement Syst."},{"key":"10.1016\/j.talanta.2026.130079_bib481","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1084\/jem.163.4.837","article-title":"Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b","volume":"163","author":"Seya","year":"1986","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib482","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/978-1-62703-724-2_29","article-title":"Functional analysis of CD59 using complement-dependent cytotoxicity assay","volume":"1100","author":"Kolev","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.talanta.2026.130079_bib483","first-page":"341","article-title":"Detection of CD59 using flow cytometry","volume":"vol.1100","author":"Kolev","year":"2014"},{"key":"10.1016\/j.talanta.2026.130079_bib484","doi-asserted-by":"crossref","unstructured":"C.J. Parker, Isolation and functional assay of the membrane complement inhibitors CD55 (DAF) and CD59 (MIRL), Curr. Protoc. Immunol. Chapter 13 (2001) 13.5.1-13.5.18. https:\/\/doi.org\/10.1002\/0471142735.im1305s11.","DOI":"10.1002\/0471142735.im1305s11"},{"key":"10.1016\/j.talanta.2026.130079_bib485","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.humimm.2013.01.011","article-title":"Use of complement regulators, CD35, CD46, CD55, and CD59, on leukocytes as markers for diagnosis of viral and bacterial infections","volume":"74","author":"Nuutila","year":"2013","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib486","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jim.2018.02.004","article-title":"CRISPR\/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as a tool for complement research","volume":"456","author":"Thielen","year":"2018","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.talanta.2026.130079_bib487","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.3389\/fimmu.2019.02072","article-title":"Altered Expression of Complement Regulatory Proteins CD35, CD46, CD55, and CD59 on Leukocyte Subsets in Individuals Suffering From Coronary Artery Disease","volume":"10","author":"Mishra","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib488","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.autrev.2008.06.002","article-title":"Immune complex clearance by complement receptor type 1 in SLE","volume":"8","author":"Kavai","year":"2008","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.talanta.2026.130079_bib489","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1002\/art.20561","article-title":"Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus","volume":"50","author":"Manzi","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.talanta.2026.130079_bib490","first-page":"1320","article-title":"Erythrocyte complement receptor type 1 in patients with systemic lupus erythematosus","volume":"16","author":"Yen","year":"1989","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.talanta.2026.130079_bib491","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2334-6-11","article-title":"Measurement of complement receptor 1 on neutrophils in bacterial and viral pneumonia","volume":"6","author":"Hohenthal","year":"2006","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.talanta.2026.130079_bib492","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1126\/science.118.3077.733","article-title":"The immune-adherence phenomenon; an immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis","volume":"118","author":"Nelson","year":"1953","journal-title":"Science"},{"key":"10.1016\/j.talanta.2026.130079_bib493","doi-asserted-by":"crossref","first-page":"7696","DOI":"10.1016\/S0021-9258(17)37343-X","article-title":"Quantitative analysis of C4b dimer binding to distinct sites on the C3b\/C4b receptor (CR1)","volume":"269","author":"Reilly","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.talanta.2026.130079_bib494","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1126\/science.2371562","article-title":"Soluble Human Complement Receptor Type 1: In Vivo Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and Necrosis","volume":"249","author":"Weisman","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.talanta.2026.130079_bib495","first-page":"229","article-title":"Low ionic strength or chemical cross-linking of monomeric C3b increases its binding affinity to the human complement C3b receptor","volume":"48","author":"Arnaout","year":"1983","journal-title":"Immunology"},{"key":"10.1016\/j.talanta.2026.130079_bib496","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.4049\/jimmunol.127.4.1348","article-title":"Characterization of the human complement (c3b) receptor with a fluid phase C3b dimer","volume":"127","author":"Arnaout","year":"1981","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib497","doi-asserted-by":"crossref","first-page":"13236","DOI":"10.1073\/pnas.1106746108","article-title":"Unique structure of iC3b resolved at a resolution of 24 \u00c5 by 3D-electron microscopy","volume":"108","author":"Alcorlo","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.talanta.2026.130079_bib498","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.4049\/jimmunol.172.3.1670","article-title":"The C4A and C4B isotypic forms of human complement fragment C4b have the same intrinsic affinity for complement receptor 1 (CR1\/CD35)","volume":"172","author":"Clemenza","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib499","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1074-7613(00)80356-8","article-title":"Complement Receptor Type 1 (CR1, CD35) Is a Receptor for C1q","volume":"7","author":"Klickstein","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.talanta.2026.130079_bib500","first-page":"78","article-title":"Application of protein A-rosette assay for screening of monoclonal antibodies to human complement regulatory proteins","volume":"7","author":"Seya","year":"1990","journal-title":"Complement Inflamm."},{"key":"10.1016\/j.talanta.2026.130079_bib501","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.4049\/jimmunol.135.4.2661","article-title":"Purification and functional analysis of the polymorphic variants of the C3b\/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF)","volume":"135","author":"Seya","year":"1985","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib502","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1042\/bj2100567","article-title":"Enzymic assay of C3b receptor on intact cells and solubilized cells","volume":"210","author":"Sim","year":"1983","journal-title":"Biochem. J."},{"key":"10.1016\/j.talanta.2026.130079_bib503","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/cyto.990120712","article-title":"Flow cytometric assay for phagocytosis of human monocytes mediated via Fc gamma-receptors and complement receptor CR1 (CD35)","volume":"12","author":"Andoh","year":"1991","journal-title":"Cytometry"},{"key":"10.1016\/j.talanta.2026.130079_bib504","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0022-1759(87)90031-7","article-title":"Enumeration of CR1 complement receptors on erythrocytes using a new method for detecting low density cell surface antigens by flow cytometry","volume":"99","author":"Cohen","year":"1987","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.talanta.2026.130079_bib505","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0022-1759(97)00198-1","article-title":"An enzyme based assay for the measurement of complement mediated binding of immune complexes to red blood cells","volume":"211","author":"Rafnar","year":"1998","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.talanta.2026.130079_bib506","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1081\/IAS-100104712","article-title":"Validation of an ELISA for the quantitation of human complement receptor 1","volume":"22","author":"Sivasankar","year":"2001","journal-title":"J. Immunoassay Immunochem."},{"key":"10.1016\/j.talanta.2026.130079_bib507","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0165-2478(94)90141-4","article-title":"Development of an ELISA assay for soluble CD35 (C3b\/C4b receptor): high levels of soluble CD35 in LE-positive patients with hematological malignancies","volume":"41","author":"Hara","year":"1994","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.talanta.2026.130079_bib508","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-1759(02)00368-X","article-title":"A simple method for accurate quantification of complement receptor 1 on erythrocytes preserved by fixing or freezing","volume":"271","author":"Cockburn","year":"2002","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.talanta.2026.130079_bib509","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107451","article-title":"Mechanistic insights into complement pathway inhibition by CR1 domain duplication","volume":"300","author":"Wymann","year":"2024","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.talanta.2026.130079_bib510","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00439-018-1883-2","article-title":"Complement receptor 1 gene (CR1) intragenic duplication and risk of Alzheimer's disease","volume":"137","author":"Kucukkilic","year":"2018","journal-title":"Hum. Genet."},{"key":"10.1016\/j.talanta.2026.130079_bib511","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2021.113469","article-title":"Label-free real-time monitoring of the BCR-triggered activation of primary human B cells modulated by the simultaneous engagement of inhibitory receptors","volume":"191","author":"Kliment","year":"2021","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/j.talanta.2026.130079_bib512","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2019.112646","article-title":"Automated flow cytometry enables high performance point-of-care analysis of leukocyte phenotypes","volume":"474","author":"Spijkerman","year":"2019","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.talanta.2026.130079_bib513","doi-asserted-by":"crossref","first-page":"6960","DOI":"10.1038\/s41467-025-62229-4","article-title":"Single urinary extracellular vesicle proteomics identifies complement receptor CD35 as a biomarker for sepsis-associated acute kidney injury","volume":"16","author":"Li","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.talanta.2026.130079_bib514","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40246-015-0029-z","article-title":"Complement regulator CD46: genetic variants and disease associations","volume":"9","author":"Liszewski","year":"2015","journal-title":"Hum. Genom."},{"key":"10.1016\/j.talanta.2026.130079_bib515","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1073\/pnas.82.3.859","article-title":"Identification of an additional class of C3-binding membrane proteins of human peripheral blood leukocytes and cell lines","volume":"82","author":"Cole","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.talanta.2026.130079_bib516","doi-asserted-by":"crossref","first-page":"37692","DOI":"10.1074\/jbc.M004650200","article-title":"Dissecting sites important for complement regulatory activity in membrane cofactor protein (MCP; CD46)","volume":"275","author":"Liszewski","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.talanta.2026.130079_bib517","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1084\/jem.175.6.1547","article-title":"Membrane cofactor protein (CD46) protects cells from complement-mediated attack by an intrinsic mechanism","volume":"175","author":"Oglesby","year":"1992","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib518","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.4049\/jimmunol.147.9.3005","article-title":"Contribution of the repeating domains of membrane cofactor protein (CD46) of the complement system to ligand binding and cofactor activity","volume":"147","author":"Adams","year":"1991","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib519","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1172\/JCI114196","article-title":"Membrane cofactor protein of complement is present on human fibroblast, epithelial, and endothelial cells","volume":"84","author":"McNearney","year":"1989","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.talanta.2026.130079_bib520","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/eji.1830180821","article-title":"Distribution of membrane cofactor protein of complement on human peripheral blood cells. An altered form is found on granulocytes","volume":"18","author":"Seya","year":"1988","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib521","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1128\/JVI.79.12.7503-7513.2005","article-title":"Localization of regions in CD46 that interact with adenovirus","volume":"79","author":"Gaggar","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.talanta.2026.130079_bib522","doi-asserted-by":"crossref","first-page":"15148","DOI":"10.1074\/jbc.270.25.15148","article-title":"Diversity of sites for measles virus binding and for inactivation of complement C3b and C4b on membrane cofactor protein CD46","volume":"270","author":"Iwata","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.talanta.2026.130079_bib523","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01587-25","article-title":"CD46 is a cellular receptor for species D human adenovirus","volume":"16","author":"Danskog","year":"2025","journal-title":"mBio"},{"key":"10.1016\/j.talanta.2026.130079_bib524","doi-asserted-by":"crossref","first-page":"14429","DOI":"10.1128\/JVI.79.22.14429-14436.2005","article-title":"CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7","volume":"79","author":"Marttila","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.talanta.2026.130079_bib525","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/nm952","article-title":"CD46 is a cellular receptor for group B adenoviruses","volume":"9","author":"Gaggar","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib526","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0165-0378(96)00967-9","article-title":"Soluble CD46 (membrane cofactor protein, MCP) in human reproductive tract fluids","volume":"31","author":"McLaughlin","year":"1996","journal-title":"J. Reprod. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib527","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2249.1992.tb06986.x","article-title":"Soluble forms of membrane cofactor protein (CD46, MCP) are present in plasma, tears, and seminal fluid in normal subjects","volume":"89","author":"Hara","year":"1992","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib528","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/intimm\/7.5.727","article-title":"Purification and functional properties of soluble forms of membrane cofactor protein (CD46) of complement: identification of forms increased in cancer patients' sera","volume":"7","author":"Seya","year":"1995","journal-title":"Int. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib529","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1046\/j.1365-2249.1999.00917.x","article-title":"Elevated serum levels of soluble membrane cofactor protein (CD46, MCP) in patients with systemic lupus erythematosus (SLE)","volume":"116","author":"Kawano","year":"1999","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib530","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1006\/clim.2000.4847","article-title":"Urine levels of CD46 (membrane cofactor protein) are increased in patients with glomerular diseases","volume":"95","author":"Shoji","year":"2000","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib531","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105184","article-title":"Soluble CD46 as a diagnostic marker of hepatic steatosis","volume":"104","author":"Bitterer","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.talanta.2026.130079_bib532","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e40841","article-title":"Proteolytic shedding of CD46 from human hepatocytes indicates liver stress","volume":"10","author":"Kupke","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.talanta.2026.130079_bib533","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.4049\/jimmunol.156.11.4415","article-title":"Membrane cofactor protein (MCP; CD46). Isoforms differ in protection against the classical pathway of complement","volume":"156","author":"Liszewski","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib534","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0966-3274(93)90002-P","article-title":"Different membrane cofactor protein (CD46) isoforms protect transfected cells against antibody and complement mediated lysis","volume":"1","author":"Loveland","year":"1993","journal-title":"Transpl. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib535","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF00216692","article-title":"Alternatively spliced RNAs encode several isoforms of CD46 (MCP), a regulator of complement activation","volume":"33","author":"Purcell","year":"1991","journal-title":"Immunogenetics"},{"key":"10.1016\/j.talanta.2026.130079_bib536","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0006-291X(05)81178-7","article-title":"Identification of four different CD46 (MCP) molecules with anti-peptide antibodies","volume":"180","author":"Purcell","year":"1991","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.talanta.2026.130079_bib537","doi-asserted-by":"crossref","DOI":"10.1038\/srep35406","article-title":"Non-random pairing of CD46 isoforms with skewing towards BC2 and C2 in activated and memory\/effector T cells","volume":"6","author":"Hansen","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.talanta.2026.130079_bib538","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/eji.202249838","article-title":"Novel homozygous CD46 variant with C-isoform expression affects C3b inactivation in atypical hemolytic uremic syndrome","volume":"52","author":"Schack","year":"2022","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib539","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/ckj\/sfx078","article-title":"Mutations in membrane cofactor protein (CD46) gene in Indian children with hemolytic uremic syndrome","volume":"11","author":"Khandelwal","year":"2018","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.talanta.2026.130079_bib540","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood-2007-04-084533","article-title":"Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome","volume":"111","author":"Fang","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.talanta.2026.130079_bib541","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.molimm.2006.07.004","article-title":"Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome","volume":"44","author":"Richards","year":"2007","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib542","doi-asserted-by":"crossref","first-page":"12966","DOI":"10.1073\/pnas.2135497100","article-title":"Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome","volume":"100","author":"Richards","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.talanta.2026.130079_bib543","first-page":"1139","article-title":"Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas","volume":"148","author":"M\u00e4enp\u00e4\u00e4","year":"1996","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.talanta.2026.130079_bib544","first-page":"1039","article-title":"Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis","volume":"74","author":"Gorter","year":"1996","journal-title":"Lab. Invest."},{"key":"10.1016\/j.talanta.2026.130079_bib545","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4049\/jimmunol.145.1.238","article-title":"Quantitative analysis of membrane cofactor protein (MCP) of complement. High expression of MCP on human leukemia cell lines, which is down-regulated during cell differentiation","volume":"145","author":"Seya","year":"1990","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib546","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1002\/eji.200424969","article-title":"Complement inhibitor membrane cofactor protein (MCP; CD46) is constitutively shed from cancer cell membranes in vesicles and converted by a metalloproteinase to a functionally active soluble form","volume":"34","author":"Hakulinen","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib547","first-page":"4943","article-title":"CD46 expression is indicative of shorter revival-free survival for ovarian cancer patients","volume":"26","author":"Surowiak","year":"2006","journal-title":"Anticancer Res."},{"key":"10.1016\/j.talanta.2026.130079_bib548","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/PAI.0b013e31821a0be9","article-title":"CD46 Expression is an unfavorable prognostic factor in breast cancer cases","volume":"19","author":"Maciejczyk","year":"2011","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.talanta.2026.130079_bib549","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.knosys.2012.09.011","article-title":"Wavelet feature extraction and genetic algorithm for biomarker detection in colorectal cancer data","volume":"37","author":"Liu","year":"2013","journal-title":"Knowl. Base Syst."},{"key":"10.1016\/j.talanta.2026.130079_bib550","article-title":"The complement regulatory protein CD46 serves as a novel biomarker for cervical cancer diagnosis and prognosis evaluation","volume":"15","author":"Yu","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib551","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1172\/JCI85856","article-title":"Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells","volume":"126","author":"Sherbenou","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.talanta.2026.130079_bib552","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO-24-01989","article-title":"First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer","volume":"43","author":"Aggarwal","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.talanta.2026.130079_bib553","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13046-023-02636-x","article-title":"CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment","volume":"42","author":"Li","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.talanta.2026.130079_bib554","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1158\/1078-0432.CCR-22-3291","article-title":"Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy","volume":"29","author":"Bidkar","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.talanta.2026.130079_bib555","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1158\/1078-0432.CCR-20-3310","article-title":"Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET","volume":"27","author":"Wang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.talanta.2026.130079_bib556","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121497","article-title":"Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer","volume":"3","author":"Su","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.talanta.2026.130079_bib557","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1158\/1078-0432.CCR-23-2130","article-title":"CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma","volume":"30","author":"Wadhwa","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.talanta.2026.130079_bib558","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.exphem.2006.03.002","article-title":"Oncolytic measles virus targets high CD46 expression on multiple myeloma cells","volume":"34","author":"Ong","year":"2006","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.talanta.2026.130079_bib559","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/725684","article-title":"Diminished expression of complement regulatory proteins on peripheral blood cells from systemic lupus erythematosus patients","volume":"2012","author":"Alegretti","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib560","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1177\/0961203306071916","article-title":"Diminished expression of complement regulatory proteins (CD55 and CD59) in lymphocytes from systemic lupus erythematosus patients with lymphopenia","volume":"15","author":"Garc\u00eda-Valladares","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.talanta.2026.130079_bib561","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/em.21924","article-title":"Human erythrocyte PIG-A assay: an easily monitored index of gene mutation requiring low volume blood samples","volume":"56","author":"Dertinger","year":"2015","journal-title":"Environ. Mol. Mutagen."},{"key":"10.1016\/j.talanta.2026.130079_bib562","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1054\/bjoc.2000.1570","article-title":"CD55 is over-expressed in the tumour environment","volume":"84","author":"Li","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.talanta.2026.130079_bib563","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/eji.1830240722","article-title":"Expression and function of CD59 on colonic adenocarcinoma cells","volume":"24","author":"Bj\u00f8rge","year":"1994","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib564","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/bjc.1993.456","article-title":"Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium","volume":"68","author":"Koretz","year":"1993","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.talanta.2026.130079_bib565","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/bjc.1992.365","article-title":"Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas","volume":"66","author":"Koretz","year":"1992","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.talanta.2026.130079_bib566","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.3892\/ijo.2016.3408","article-title":"The membrane complement regulatory protein CD59 promotes tumor growth and predicts poor prognosis in breast cancer","volume":"48","author":"Ouyang","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.talanta.2026.130079_bib567","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1158\/1078-0432.CCR-1073-03","article-title":"Loss of CD55 is associated with aggressive breast tumors","volume":"10","author":"Madjd","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.talanta.2026.130079_bib568","first-page":"820","article-title":"Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells","volume":"71","author":"Hakulinen","year":"1994","journal-title":"Lab. Invest."},{"key":"10.1016\/j.talanta.2026.130079_bib569","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1593\/neo.05679","article-title":"Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo","volume":"8","author":"Loberg","year":"2006","journal-title":"Neoplasia"},{"key":"10.1016\/j.talanta.2026.130079_bib570","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/(SICI)1097-0215(19970611)71:6<1049::AID-IJC22>3.0.CO;2-7","article-title":"Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer","volume":"71","author":"Jarvis","year":"1997","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.talanta.2026.130079_bib571","doi-asserted-by":"crossref","first-page":"E34","DOI":"10.25011\/cim.v35i1.16104","article-title":"Increased expression of CD55 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma","volume":"35","author":"Shen","year":"2012","journal-title":"Clin. Invest. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib572","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3892\/ol.2014.2751","article-title":"Expression and prognostic value of CD97 and its ligand CD55 in pancreatic cancer","volume":"9","author":"He","year":"2015","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.talanta.2026.130079_bib573","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1084\/jem.20170438","article-title":"CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors","volume":"214","author":"Saygin","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib574","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.imlet.2015.06.017","article-title":"CD55, CD59, factor H and factor H-like 1 gene expression analysis in tumors of the ovary and corpus uteri origin","volume":"167","author":"Kapka-Skrzypczak","year":"2015","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.talanta.2026.130079_bib575","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/1097-4652(200012)185:3<317::AID-JCP1>3.0.CO;2-L","article-title":"Overexpression of protectin (CD59) down-modulates the susceptibility of human melanoma cells to homologous complement","volume":"185","author":"Coral","year":"2000","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.talanta.2026.130079_bib576","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1158\/1078-0432.CCR-08-1685","article-title":"In vivo model of follicular lymphoma resistant to rituximab","volume":"15","author":"Dalle","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.talanta.2026.130079_bib577","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0165-5728(02)00306-5","article-title":"Expression of the EGF-TM7 receptor CD97 and its ligand CD55 (DAF) in multiple sclerosis","volume":"132","author":"Visser","year":"2002","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.talanta.2026.130079_bib578","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0019-2791(69)90297-3","article-title":"Inhibition of complement by a substance isolated from human erythrocytes. II. Studies on the site and mechanism of action","volume":"6","author":"Hoffmann","year":"1969","journal-title":"Immunochemistry"},{"key":"10.1016\/j.talanta.2026.130079_bib579","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0019-2791(69)90296-1","article-title":"Inhibition of complement by a substance isolated from human erythrocytes. I. Extraction from human erythrocyte stromata","volume":"6","author":"Hoffman","year":"1969","journal-title":"Immunochemistry"},{"key":"10.1016\/j.talanta.2026.130079_bib580","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4049\/jimmunol.129.1.184","article-title":"Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system","volume":"129","author":"Nicholson-Weller","year":"1982","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib581","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1365-2141.1989.tb00260.x","article-title":"Studies on the sensitivity to complement-mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (decay accelerating factor)","volume":"73","author":"Merry","year":"1989","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.talanta.2026.130079_bib582","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1084\/jem.166.5.1221","article-title":"The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb","volume":"166","author":"Fujita","year":"1987","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib583","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1128\/IAI.70.8.4485-4493.2002","article-title":"Structure-function analysis of decay-accelerating factor: identification of residues important for binding of the Escherichia coli Dr adhesin and complement regulation","volume":"70","author":"Hasan","year":"2002","journal-title":"Infect. Immun."},{"key":"10.1016\/j.talanta.2026.130079_bib584","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.4049\/jimmunol.156.7.2528","article-title":"Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor","volume":"156","author":"Brodbeck","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib585","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.4049\/jimmunol.149.9.2906","article-title":"Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor","volume":"149","author":"Coyne","year":"1992","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib586","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1073\/pnas.0307200101","article-title":"Complement regulation at the molecular level: the structure of decay-accelerating factor","volume":"101","author":"Lukacik","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.talanta.2026.130079_bib587","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1110\/ps.03455604","article-title":"Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli","volume":"13","author":"White","year":"2004","journal-title":"Protein Sci."},{"key":"10.1016\/j.talanta.2026.130079_bib588","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1074\/jbc.M410179200","article-title":"Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55)","volume":"280","author":"Harris","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.talanta.2026.130079_bib589","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.lab.2003.11.004","article-title":"Increased serum concentrations and surface expression on peripheral white blood cells of decay-accelerating factor (CD55) in patients with active ulcerative colitis","volume":"143","author":"Makidono","year":"2004","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib590","first-page":"1136","article-title":"Expression of two molecular forms of the complement decay-accelerating factor in the eye and lacrimal gland","volume":"31","author":"Lass","year":"1990","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.talanta.2026.130079_bib591","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1084\/jem.165.3.848","article-title":"Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids","volume":"165","author":"Medof","year":"1987","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib592","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/eji.200323381","article-title":"CD55\/decay accelerating factor is part of the lipopolysaccharide-induced receptor complex","volume":"33","author":"Heine","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib593","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/09680519010070030601","article-title":"Decay-accelerating factor (DAF\/CD55) is a functional active element of the LPS receptor complex","volume":"7","author":"Heine","year":"2001","journal-title":"J. Endotoxin Res."},{"key":"10.1016\/j.talanta.2026.130079_bib594","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1111\/j.1572-0241.2003.08672.x","article-title":"Testing of multiple samples increases the sensitivity of stool decay-accelerating factor test for the detection of colorectal cancer","volume":"98","author":"Mizuno","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.talanta.2026.130079_bib595","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1081\/IAS-120015480","article-title":"Advances in the development of a reliable assay for the measurement of stool decay-accelerating factor in the detection of colorectal cancer","volume":"23","author":"Iwagaki","year":"2002","journal-title":"J. Immunoassay Immunochem."},{"key":"10.1016\/j.talanta.2026.130079_bib596","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1365-2249.1998.00573.x","article-title":"Decay-accelerating factor (DAF) in stool specimens as a marker of disease activity in patients with ulcerative colitis (UC)","volume":"112","author":"Inaba","year":"1998","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib597","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/0016-5085(95)90390-9","article-title":"Detection of decay-accelerating factor in stool specimens of patients with colorectal cancer","volume":"109","author":"Mizuno","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.talanta.2026.130079_bib598","article-title":"A Single-Molecule Bioelectronic Portable Array for Early Diagnosis of Pancreatic Cancer Precursors","volume":"35","author":"Genco","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.talanta.2026.130079_bib599","doi-asserted-by":"crossref","unstructured":"A. Beric, S. Sahin, S. Sanchez, Z. Yang, R. Kumar, I. Alfradique-Dunham, J. Sanford, D. Western, B. Phillips, J.P. Budde, R.J. Perrin, P.T. Kotzbauer, J.S. Perlmutter, S.A. Norris, C. Cruchaga, L. Ibanez, Study of blood linear RNA nominates CD55 and DLD as early-stage biomarkers for Parkinson's disease, Brain. https:\/\/doi.org\/10.1093\/brain\/awag014.","DOI":"10.1093\/brain\/awag014"},{"key":"10.1016\/j.talanta.2026.130079_bib600","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2147\/CIA.S536479","article-title":"Association of Decay Accelerating Factor (CD55) Positive Extracellular Vesicles with Advanced Age and Blood Glucose Levels in Elderly Individuals","volume":"20","author":"Yue","year":"2025","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.talanta.2026.130079_bib601","doi-asserted-by":"crossref","first-page":"8960","DOI":"10.1038\/s41598-018-27355-8","article-title":"Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer","volume":"8","author":"Dho","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.talanta.2026.130079_bib602","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.2147\/DDDT.S182337","article-title":"A study on screening and antitumor effect of CD55-specific ligand peptide in cervical cancer cells","volume":"12","author":"Li","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.talanta.2026.130079_bib603","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s43046-025-00299-7","article-title":"The decay-accelerating factor (CD55) in acute leukemia patients and its query implication in cancer pathogenesis","volume":"37","author":"Abdelaziz","year":"2025","journal-title":"J. Egypt. Natl. Cancer Inst."},{"key":"10.1016\/j.talanta.2026.130079_bib604","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0161-5890(89)90097-7","article-title":"Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol","volume":"26","author":"Stefanov\u00e1","year":"1989","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib605","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/intimm\/1.2.205","article-title":"A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement","volume":"1","author":"Okada","year":"1989","journal-title":"Int. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib606","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1172\/JCI114172","article-title":"Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria","volume":"84","author":"Holguin","year":"1989","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.talanta.2026.130079_bib607","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.4049\/jimmunol.142.9.3013","article-title":"A 19-kDa human erythrocyte molecule H19 is involved in rosettes, present on nucleated cells, and required for T cell activation. Comparison of the roles of H19 and LFA-3 molecules in T cell activation","volume":"142","author":"Groux","year":"1989","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib608","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1084\/jem.170.3.637","article-title":"CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells","volume":"170","author":"Davies","year":"1989","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib609","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/oxfordjournals.jbchem.a122524","article-title":"Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels","volume":"104","author":"Sugita","year":"1988","journal-title":"J. Biochem."},{"key":"10.1016\/j.talanta.2026.130079_bib610","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.4049\/jimmunol.146.7.2345","article-title":"Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9","volume":"146","author":"Rollins","year":"1991","journal-title":"J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib611","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1365-2249.1991.tb05623.x","article-title":"The complement-inhibiting protein, protectin (CD59 antigen), is present and functionally active on glomerular epithelial cells","volume":"83","author":"Rooney","year":"1991","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib612","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1084\/jem.172.1.367","article-title":"Human protectin (CD59), an 18-20-kD homologous complement restriction factor, does not restrict perforin-mediated lysis","volume":"172","author":"Meri","year":"1990","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib613","first-page":"1","article-title":"Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers","volume":"71","author":"Meri","year":"1990","journal-title":"Immunology"},{"key":"10.1016\/j.talanta.2026.130079_bib614","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/cyto.b.21030","article-title":"A simple flow cytometric assay for routine paroxysmal nocturnal hemoglobinuria testing based on immature reticulocytes and granulocytes","volume":"82","author":"Tsagarakis","year":"2012","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.talanta.2026.130079_bib615","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/s41467-023-36441-z","article-title":"Structural basis for membrane attack complex inhibition by CD59","volume":"14","author":"Couves","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.talanta.2026.130079_bib616","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.str.2016.06.017","article-title":"Structural Basis for Receptor Recognition by the Human CD59-Responsive Cholesterol-Dependent Cytolysins","volume":"24","author":"Lawrence","year":"2016","journal-title":"Structure"},{"key":"10.1016\/j.talanta.2026.130079_bib617","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.celrep.2013.04.029","article-title":"Structural basis for recognition of the pore-forming toxin intermedilysin by human complement receptor CD59","volume":"3","author":"Johnson","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.talanta.2026.130079_bib618","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/s41419-018-0895-0","article-title":"CD59 is a potential biomarker of esophageal squamous cell carcinoma radioresistance by affecting DNA repair","volume":"9","author":"Zhou","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.talanta.2026.130079_bib619","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1046\/j.1365-3083.2000.00783.x","article-title":"Detection of a soluble form of the complement membrane attack complex inhibitor CD59 in plasma after acute myocardial infarction","volume":"52","author":"V\u00e4kev\u00e4","year":"2000","journal-title":"Scand. J. Immunol."},{"issue":"Pt 3","key":"10.1016\/j.talanta.2026.130079_bib620","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1042\/bj3160923","article-title":"Structural composition and functional characterization of soluble CD59: heterogeneity of the oligosaccharide and glycophosphoinositol (GPI) anchor revealed by laser-desorption mass spectrometric analysis","volume":"316","author":"Meri","year":"1996","journal-title":"Biochem. J."},{"key":"10.1016\/j.talanta.2026.130079_bib621","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/ki.1995.197","article-title":"Urinary excretion of protectin (CD59), complement SC5b-9 and cytokines in membranous glomerulonephritis","volume":"47","author":"Lehto","year":"1995","journal-title":"Kidney Int."},{"key":"10.1016\/j.talanta.2026.130079_bib622","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1084\/jem.177.5.1409","article-title":"Physiologic relevance of the membrane attack complex inhibitory protein CD59 in human seminal plasma: CD59 is present on extracellular organelles (prostasomes), binds cell membranes, and inhibits complement-mediated lysis","volume":"177","author":"Rooney","year":"1993","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib623","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0165-2478(93)90058-A","article-title":"Soluble CD59 in pregnancy and infancy","volume":"36","author":"Bj\u00f8rge","year":"1993","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.talanta.2026.130079_bib624","first-page":"541","article-title":"Characterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid","volume":"76","author":"Rooney","year":"1992","journal-title":"Immunology"},{"key":"10.1016\/j.talanta.2026.130079_bib625","first-page":"193","article-title":"Soluble forms of CD59-antigen: distribution in body fluids and functional activity","author":"Meri","year":"1991","journal-title":"Complement Inflamm."},{"key":"10.1016\/j.talanta.2026.130079_bib626","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/ajh.23478","article-title":"A specific and sensitive assay for blood levels of glycated CD59: a novel biomarker for diabetes","volume":"88","author":"Ghosh","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.talanta.2026.130079_bib627","doi-asserted-by":"crossref","DOI":"10.1038\/srep26274","article-title":"Soluble CD59 is a Novel Biomarker for the Prediction of Obstructive Chronic Lung Allograft Dysfunction After Lung Transplantation","volume":"6","author":"Budding","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.talanta.2026.130079_bib628","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/cmi.2009.8","article-title":"CD59 silencing via retrovirus-mediated RNA interference enhanced complement-mediated cell damage in ovary cancer","volume":"6","author":"Shi","year":"2009","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib629","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202422673","article-title":"Macrocyclic Peptide Probes for Immunomodulatory Protein CD59: Potent Modulators of Bacterial Toxin Activity and Antibody-Dependent Cytotoxicity","volume":"64","author":"Bickel","year":"2025","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.talanta.2026.130079_bib630","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2024.2314322","article-title":"CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells","volume":"25","author":"Wang","year":"2024","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.talanta.2026.130079_bib631","doi-asserted-by":"crossref","first-page":"12109","DOI":"10.1074\/jbc.M113.547083","article-title":"Rapid degradation of the complement regulator, CD59, by a novel inhibitor","volume":"289","author":"Cai","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.talanta.2026.130079_bib632","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/cmi.2010.35","article-title":"Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells","volume":"8","author":"You","year":"2011","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib633","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/0008-5472.CAN-10-3016","article-title":"Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis","volume":"71","author":"Hu","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.talanta.2026.130079_bib634","doi-asserted-by":"crossref","DOI":"10.1016\/j.jviromet.2024.115096","article-title":"Comparing methods to detect cellular proteins on the surface of HIV-1 virions","volume":"333","author":"Chaphekar","year":"2025","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.talanta.2026.130079_bib635","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.molimm.2021.10.006","article-title":"Complement multiplex testing: Concept, promises and pitfalls","volume":"140","author":"Proh\u00e1szka","year":"2021","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib636","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.4155\/bio.13.342","article-title":"Miniaturization of multiplexed planar recombinant antibody arrays for serum protein profiling","volume":"6","author":"Petersson","year":"2014","journal-title":"Bioanalysis"},{"key":"10.1016\/j.talanta.2026.130079_bib637","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1225","article-title":"Quantitative multiplex profiling of the complement system to diagnose complement-mediated diseases","volume":"9","author":"Willems","year":"2020","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib638","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2023.117750","article-title":"Usefulness and analytical performances of complement multiplex assay for measuring complement biomarkers in plasma","volume":"554","author":"Meuleman","year":"2024","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.talanta.2026.130079_bib639","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ekir.2020.01.018","article-title":"Proteomic Analysis of Complement Proteins in Membranous Nephropathy","volume":"5","author":"Ravindran","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.talanta.2026.130079_bib640","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1212\/WNL.0000000000007850","article-title":"Exploratory proteomic analysis implicates the alternative complement cascade in primary CNS vasculitis","volume":"93","author":"Mandel-Brehm","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.talanta.2026.130079_bib641","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jim.2013.01.009","article-title":"Distribution and determinants of circulating complement factor H concentration determined by a high-throughput immunonephelometric assay","volume":"390","author":"Sofat","year":"2013","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.talanta.2026.130079_bib642","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22627","article-title":"Quantification of human C1 esterase inhibitor protein using an automated turbidimetric immunoassay","volume":"33","author":"Tange","year":"2019","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.talanta.2026.130079_bib643","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1515\/cclm-2024-0024","article-title":"Quantification of C1 inhibitor activity using a chromogenic automated assay: analytical and clinical performances","volume":"62","author":"Renaudineau","year":"2024","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib644","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1208\/s12248-018-0266-x","article-title":"A Gyrolab Assay for the Quantitation of Free Complement Protein C5a in Human Plasma","volume":"20","author":"Dysinger","year":"2018","journal-title":"AAPS J."},{"key":"10.1016\/j.talanta.2026.130079_bib645","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jmsacl.2024.10.004","article-title":"Research letter: Pilot study of a prototype fully automated mass spectrometry system for routine clinical laboratory use","volume":"34","author":"Vogeser","year":"2024","journal-title":"J. Mass Spectrom. Adv. Clin. Lab"},{"key":"10.1016\/j.talanta.2026.130079_bib646","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/13102818.2022.2053342","article-title":"Enhancing precision medicine through clinical mass spectrometry platform","volume":"36","author":"Hristova","year":"2022","journal-title":"Biotechnol. Biotechnol. Equip."},{"key":"10.1016\/j.talanta.2026.130079_bib647","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jim.2009.11.003","article-title":"Preparing serum for functional complement assays","volume":"352","author":"Lachmann","year":"2010","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.talanta.2026.130079_bib648","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2025.113825","article-title":"Complement function and activation in human serum and plasma collected in different blood collection tubes","volume":"538","author":"Andersson","year":"2025","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.talanta.2026.130079_bib649","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1007102","article-title":"Pitfalls in complement analysis: A systematic literature review of assessing complement activation","volume":"13","author":"Brandwijk","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib650","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3389\/fimmu.2018.02664","article-title":"Age and Sex-Associated Changes of Complement Activity and Complement Levels in a Healthy Caucasian Population","volume":"9","author":"Da Gaya Costa","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib651","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/sji.12154","article-title":"Complement profile in neonates of different gestational ages","volume":"79","author":"Grumach","year":"2014","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib652","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1046\/j.1365-3083.2003.01326.x","article-title":"Ontogeny of complement regulatory proteins - concentrations of factor h, factor I, c4b-binding protein, properdin and vitronectin in healthy children of different ages and in adults","volume":"58","author":"de Paula","year":"2003","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib654","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.molimm.2013.05.221","article-title":"An international serum standard for application in assays to detect human complement activation products","volume":"56","author":"Bergseth","year":"2013","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib655","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1368399","article-title":"External quality assurance program for diagnostic complement laboratories: evaluation of the results of the past seven years","volume":"15","author":"Kirschfink","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib656","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.697313","article-title":"Expanding Horizons in Complement Analysis and Quality Control","volume":"12","author":"Frazer-Abel","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib657","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.imbio.2013.06.004","article-title":"Standardisation of the factor H autoantibody assay","volume":"219","author":"Watson","year":"2014","journal-title":"Immunobiology"},{"key":"10.1016\/j.talanta.2026.130079_bib658","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.119724","article-title":"Artificial intelligence in the clinical laboratory","volume":"559","author":"Hou","year":"2024","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.talanta.2026.130079_bib659","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/10408363.2018.1561640","article-title":"Automation and artificial intelligence in the clinical laboratory","volume":"56","author":"Naugler","year":"2019","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.talanta.2026.130079_bib660","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00894-020-04472-8","article-title":"Computational analysis of complement inhibitor compstatin using molecular dynamics","volume":"26","author":"Devaurs","year":"2020","journal-title":"J. Mol. Model."},{"key":"10.1016\/j.talanta.2026.130079_bib661","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1039\/C2CP41388D","article-title":"Molecular dynamics simulations of wild type and mutants of human complement receptor 2 complexed with C3d","volume":"15","author":"Wan","year":"2013","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.talanta.2026.130079_bib662","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2024.126701","article-title":"A microfluidic chip with integrated plasma separation for sample-to-answer detection of multiple chronic disease biomarkers in whole blood","volume":"280","author":"Zhou","year":"2024","journal-title":"Talanta"},{"key":"10.1016\/j.talanta.2026.130079_bib663","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1039\/D2LC00693F","article-title":"A microfluidic plasma separation device combined with a surface plasmon resonance biosensor for biomarker detection in whole blood","volume":"23","author":"Debnath","year":"2023","journal-title":"Lab Chip"},{"key":"10.1016\/j.talanta.2026.130079_bib664","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/0142-9612(88)90066-X","article-title":"Activation of the complement system at the interface between blood and artificial surfaces","volume":"9","author":"Kazatchkine","year":"1988","journal-title":"Biomaterials"},{"key":"10.1016\/j.talanta.2026.130079_bib665","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-5223(19)37046-1","article-title":"Complement activation during major operations with or without cardiopulmonary bypass","volume":"93","author":"Fosse","year":"1987","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.talanta.2026.130079_bib666","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJM198102263040901","article-title":"Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins","volume":"304","author":"Chenoweth","year":"1981","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.talanta.2026.130079_bib667","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96910","article-title":"Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles","volume":"3","author":"Merle","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.talanta.2026.130079_bib668","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.smim.2013.05.006","article-title":"The role of complement in trauma and fracture healing","volume":"25","author":"Huber-Lang","year":"2013","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.talanta.2026.130079_bib669","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm1419","article-title":"Generation of C5a in the absence of C3: a new complement activation pathway","volume":"12","author":"Huber-Lang","year":"2006","journal-title":"Nat. Med."}],"container-title":["Talanta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039914026007356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039914026007356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:24:48Z","timestamp":1786695888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039914026007356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":668,"alternative-id":["S0039914026007356"],"URL":"https:\/\/doi.org\/10.1016\/j.talanta.2026.130079","relation":{},"ISSN":["0039-9140"],"issn-type":[{"value":"0039-9140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in analytical methods for regulatory complement proteins in research and clinical applications","name":"articletitle","label":"Article Title"},{"value":"Talanta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.talanta.2026.130079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"130079"}}